CA2738870A1 - Pyrrolidine n-benzyl derivatives - Google Patents
Pyrrolidine n-benzyl derivatives Download PDFInfo
- Publication number
- CA2738870A1 CA2738870A1 CA2738870A CA2738870A CA2738870A1 CA 2738870 A1 CA2738870 A1 CA 2738870A1 CA 2738870 A CA2738870 A CA 2738870A CA 2738870 A CA2738870 A CA 2738870A CA 2738870 A1 CA2738870 A1 CA 2738870A1
- Authority
- CA
- Canada
- Prior art keywords
- phenyl
- methyl
- benzyl
- fluoro
- dichloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Fodder In General (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
The present invention relates to a compound of formula (I) wherein Ar1 is aryl or heteroaryl; Ar2 is aryl or heteroaryl;
R1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(O)--lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
R1 is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(O)--lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl; R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano; R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen; n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different; o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different; p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different; or to a pharmaceutically active salt, to all stereoisomeric forms, including individual diastereoisomers and enantiomers as well as to racemic and non-racemic mixtures thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
Description
PYRROLIDINE N-BENZYL DERIVATIVES
The present invention relates to a compound of formula I
3) Ar2 (R2)0 P / N-/
N
(R1)nAr1 O I
wherein Ar' is aryl or heteroaryl;
Are is aryl or heteroaryl;
R' is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(O)-lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl;
R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano;
R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen;
IN n is 1, 2 or 3; in case n is 2 or 3, R' may be the same or different;
o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different;
p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different;
or to a pharmaceutically active salt thereof.
The invention includes all stereoisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof.
It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
Pop/12.06.2009 The three main mammalian tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) belong to the family of neuropeptides sharing the common COOH-terminal pentapeptide sequence of Phe-X-Gly-Leu-Met-NH2. As neurotransmitters, these peptides exert their biological activity via three distinct neurokinin (NK) receptors termed as NK- 1, NK-2 and NK-3. SP binds preferentially to the NK-1 receptor, NKA to the NK-2 and NKB to the NK-3 receptor.
The NK-3 receptor is characterized by a predominant expression in CNS and its involvement in the modulation of the central monoaminergic system has been shown. These properties make the NK-3 receptor a potential target for central nervous system disorders such as anxiety, depression, bipolar disorders, Parkinson's disease, schizophrenia and pain (Neurosci.
Letters, 2000, 283, 185 -188; Exp. Opin. Ther. Patents 2000, 10, 939-960;
Neuroscience, 1996, 74, 403-414; Neuropeptides, 1998, 32, 481-488).
Schizophrenia is one of the major neuropsychiatric disorders, characterized by severe and chronic mental impairment. This devastating disease affects about 1 % of the world's population.
Symptoms begin in early adulthood and are followed by a period of interpersonal and social dysfunction. Schizophrenia manifests as auditory and visual hallucinations, paranoia, delusions (positive symptoms), blunted affect, depression, anhedonia, poverty of speech, memory and attention deficits as well as social withdrawal (negative symptoms).
For decades scientists and clinicians have made efforts with the aim of discovering an ideal agent for the pharmacological treatment of schizophrenia. However, the complexity of the disorders, due to a wide array of symptoms, has hampered those efforts. There are no specific focal characteristics for the diagnosis of schizophrenia and no single symptom is consistently present in all patients. Consequently, the diagnosis of schizophrenia as a single disorder or as a variety of different disorders has been discussed but not yet resolved. The major difficulty in the development of a new drug for schizophrenia is the lack of knowledge about the cause and nature of this disease. Some neurochemical hypotheses have been proposed on the basis of pharmacological studies to rationalize the development of a corresponding therapy: the dopamine, the serotonin and the glutamate hypotheses. But taking into account the complexity of schizophrenia, an appropriate multireceptor affinity profile might be required for efficacy against positive and negative signs and symptoms. Furthermore, an ideal drug against schizophrenia would preferably have a low dosage allowing once-per-day dosage, due to the low adherence of schizophrenic patients.
The present invention relates to a compound of formula I
3) Ar2 (R2)0 P / N-/
N
(R1)nAr1 O I
wherein Ar' is aryl or heteroaryl;
Are is aryl or heteroaryl;
R' is hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, S-lower alkyl, -S(O)2-lower alkyl, -S(O)2-di-lower alkyl amino, cyano, amino, mono or di-lower alkyl amino, C(O)-lower alkyl, NHC(O)-lower alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by lower alkyl;
R2 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen or cyano;
R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen;
IN n is 1, 2 or 3; in case n is 2 or 3, R' may be the same or different;
o is 1, 2 or 3; in case o is 2 or 3, R2 may be the same or different;
p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different;
or to a pharmaceutically active salt thereof.
The invention includes all stereoisomeric forms, including individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof.
It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
Pop/12.06.2009 The three main mammalian tachykinins, substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) belong to the family of neuropeptides sharing the common COOH-terminal pentapeptide sequence of Phe-X-Gly-Leu-Met-NH2. As neurotransmitters, these peptides exert their biological activity via three distinct neurokinin (NK) receptors termed as NK- 1, NK-2 and NK-3. SP binds preferentially to the NK-1 receptor, NKA to the NK-2 and NKB to the NK-3 receptor.
The NK-3 receptor is characterized by a predominant expression in CNS and its involvement in the modulation of the central monoaminergic system has been shown. These properties make the NK-3 receptor a potential target for central nervous system disorders such as anxiety, depression, bipolar disorders, Parkinson's disease, schizophrenia and pain (Neurosci.
Letters, 2000, 283, 185 -188; Exp. Opin. Ther. Patents 2000, 10, 939-960;
Neuroscience, 1996, 74, 403-414; Neuropeptides, 1998, 32, 481-488).
Schizophrenia is one of the major neuropsychiatric disorders, characterized by severe and chronic mental impairment. This devastating disease affects about 1 % of the world's population.
Symptoms begin in early adulthood and are followed by a period of interpersonal and social dysfunction. Schizophrenia manifests as auditory and visual hallucinations, paranoia, delusions (positive symptoms), blunted affect, depression, anhedonia, poverty of speech, memory and attention deficits as well as social withdrawal (negative symptoms).
For decades scientists and clinicians have made efforts with the aim of discovering an ideal agent for the pharmacological treatment of schizophrenia. However, the complexity of the disorders, due to a wide array of symptoms, has hampered those efforts. There are no specific focal characteristics for the diagnosis of schizophrenia and no single symptom is consistently present in all patients. Consequently, the diagnosis of schizophrenia as a single disorder or as a variety of different disorders has been discussed but not yet resolved. The major difficulty in the development of a new drug for schizophrenia is the lack of knowledge about the cause and nature of this disease. Some neurochemical hypotheses have been proposed on the basis of pharmacological studies to rationalize the development of a corresponding therapy: the dopamine, the serotonin and the glutamate hypotheses. But taking into account the complexity of schizophrenia, an appropriate multireceptor affinity profile might be required for efficacy against positive and negative signs and symptoms. Furthermore, an ideal drug against schizophrenia would preferably have a low dosage allowing once-per-day dosage, due to the low adherence of schizophrenic patients.
In recent years clinical studies with selective NK1 and NK2 receptor antagonists appeared in the literature showing results for the treatment of emesis, depression, anxiety, pain and migraine (NK1) and asthma (NK2 and NK1). The most exciting data were produced in the treatment of chemotherapy-induced emesis, nausea and depression with NKl and in asthma with NK2- receptor antagonists. In contrast, no clinical data on NK3 receptor antagonists have appeared in the literature until 2000. Osanetant (SR 142,801) from Sanofi-Synthelabo was the first identified potent and selective non-peptide antagonist described for the NK3 tachykinin receptor for the potential treatment of schizophrenia, which was reported in the literature (Current Opinion in Investigational Drugs, 2001,2(7), 950-956 and Psychiatric Disorders Study 4, Schizophrenia, June 2003, Decision Recources, Inc., Waltham, Massachusetts). The proposed drug SR 142,801 has been shown in a phase II trial as active on positive symptoms of schizophrenia, such as altered behaviour, delusion, hallucinations, extreme emotions, excited motor activity and incoherent speech, but inactive in the treatment of negative symptoms, which are depression, anhedonia, social isolation or memory and attention deficits.
The neurokinin-3 receptor antagonists have been described as useful in pain or inflammation, as well as in schizophrenia, Exp. Opinion. Ther. Patents (2000), 10(6), 939-960 and Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 956 and Psychiatric Disorders Study 4, Schizophrenia, June 2003, Decision Recources, Inc., Waltham, Massachusetts).
Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as depression, pain, bipolar disorders, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
The preferred indications using the compounds of the present invention are depression, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
As used herein, the term "lower alkyl" denotes a straight- or branched-chain alkyl group containing from 1-8 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1-4 carbon atoms.
The term "lower alkyl substituted by halogen" denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example -CF3, -CHF2, -CH2F, -CH2CF3, -CH2CH2CF3, -CH2CF2CF3 and the like. Preferred lower alkyl substituted by halogen groups are groups having 1-4 carbon atoms.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term "cycloalkyl" denotes a saturated carbon ring containing from 3-7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclpentyl, cyclohexyl, cycloheptyl, and the like.
The term "aryl" denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 6-14 carbon atoms in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl or indanyl. Preferred is the phenyl group.
The term "heteroaryl" denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 5-14 ring atoms, preferably containing 5-10 ring atoms, in which at least one ring is aromatic in nature, and which contains at least one heteroatom, selected from N, 0 or S, for example quinoxalinyl, dihydroisoquinolinyl, pyrazin-2-yl, pyrazol-1-yl, 2,4-dihydro-pyrazol-3-one, pyridinyl, isoxazolyl, benzo[1,3]dioxol, pyridyl, pyrimidin-4-yl, pyrimidin-5-yl, benzotriazol-5-yl, benzoimidazol-5-yl, [1,3,4]-oxadiazol-2-yl, [1,2.4]triazol-1-yl, [1,6]naphthyridin-2-yl, imidazo[4,5-b]pyridine-6-yl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, furyl, imidazol-1-yl, or benzofuranyl. Preferred heteroaryl group is pyridine-2,3or 4-yl.
The term heterocyclyl denotes a five or six membered alkyl ring, wherein one or two carbon atoms are replaced by N, S or 0, for example the following groups:
morpholinyl, 1,1-dioxo-1-6-isothiazolidin-2-yl, piperazinyl, optionally substituted in 1 position by carboxylic acid tert-butyl ester or is 1,1,-dioxo-l-6-thiomorpholin-4-yl.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
Compounds of formula I, wherein Ari is aryl and Ar 2 is phenyl are preferred.
Preferred specific compounds are the followings:
4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -benzonitrile 3- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -benzonitrile 4-({ [(3RS,4SR)- 1-(4-cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amino } -methyl)-2-fluoro-benzonitrile 4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -3 -fluoro-benzonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(2-fluoro-5 -methanesulfonyl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-methanesulfonyl-phenyl)-methanone 4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl }-2-methyl-benzonitrile 1-(4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine- l -carbonyl} -phenyl)-ethanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-morpholin-4-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4- [1,2,4]triazo 1-1-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-imidazol-l-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-[4-(1,1-dioxo-l-6-isothiazolidin-2-yl)-phenyl]-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-2-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-3 -yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-4-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4- [[1,3 ,4]oxadiazol-2-yl-phenyl)-methanone N-(4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl }-phenyl)-acetamide 4- {(3 SR,4RS)-3-(4-chloro-3-fluoro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine- l -carbonyl} -benzonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l-yl}-(4-oxazol-5-yl-phenyl)-methanone or 4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-pyrrolidine-1-carbonyl} -benzonitrile.
Compounds of formula I, wherein Ari is heteroaryl and Ar 2 is phenyl are further preferred.
Preferred specific compounds are the followings:
benzo [ 1,3 ] dioxol-5-yl- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-methyl-pyridin-3-yl)-methanone 5- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -pyridine-2-carbonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-morpholin-4-yl-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-fluoro-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-(6-methoxy-pyridin-3-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-pyrazol- l -yl-pyridin-3-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(2-methyl-pyridin-4-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-hydroxy-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} - [ 1, 6]naphthyridin-2-yl-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-(2-methoxy-pyrimidin-5-yl)-methanone (3H-benzotriazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl} -methanone (3H-benzoimidazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -methanone 4-(5- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester or {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} - [6-(1, 1 -dioxo- l -6-thiomorpholin-4-yl)-pyridin-3-yl]-methanone.
The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.
The compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
The present compounds of formula I and their pharmaceutically acceptable salts may be prepared by methods, known in the art, for example by the process variants described below, which process comprises a) coupling a compound of formula (R3)P \ / \ Ark (R2)0 N-/
N
H VIII
with a suitable acid chloride or carboxylic acid of formula R-C(O)-Ari-(R')õ
wherein R is Cl or hydroxy, to a compound of formula 3) Ar2 (R2)0 P
,()'IN-/
N
(R1)nAr1 O
wherein the substituents R', R2, R3, Ar', Ar2 and the definitions o, n and p are described above, or b) alkylating a compound of formula (R 3)p N~
O
-,N
N
(R1)Art O
n XII
with a compound of formula Hal-CH2-Are-(R2)0 to a compound of formula 3) Ar2 (R2)0 P / N-/
N
(R1)nAr1 O
wherein the substituents R', R2, R3, Ar', Ar2 and the definitions o, n and p are described above, and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
The preparation of compounds of formula I is further described in more detail in schemes I - II
and in examples 1 -70.
The neurokinin-3 receptor antagonists have been described as useful in pain or inflammation, as well as in schizophrenia, Exp. Opinion. Ther. Patents (2000), 10(6), 939-960 and Current Opinion in Investigational Drugs, 2001, 2(7), 950-956 956 and Psychiatric Disorders Study 4, Schizophrenia, June 2003, Decision Recources, Inc., Waltham, Massachusetts).
Objects of the present invention are novel compounds of formula I, their manufacture, medicaments based on a compound in accordance with the invention and their production as well as the use of compounds of formula I in the control or prevention of illnesses such as depression, pain, bipolar disorders, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
The preferred indications using the compounds of the present invention are depression, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
The following definitions of the general terms used in the present description apply irrespective of whether the terms in question appear alone or in combination.
As used herein, the term "lower alkyl" denotes a straight- or branched-chain alkyl group containing from 1-8 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, n-butyl, i-butyl, t-butyl and the like. Preferred lower alkyl groups are groups with 1-4 carbon atoms.
The term "lower alkyl substituted by halogen" denotes an alkyl group as defined above, wherein at least one hydrogen atom is replaced by halogen, for example -CF3, -CHF2, -CH2F, -CH2CF3, -CH2CH2CF3, -CH2CF2CF3 and the like. Preferred lower alkyl substituted by halogen groups are groups having 1-4 carbon atoms.
The term "halogen" denotes chlorine, iodine, fluorine and bromine.
The term "cycloalkyl" denotes a saturated carbon ring containing from 3-7 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclpentyl, cyclohexyl, cycloheptyl, and the like.
The term "aryl" denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 6-14 carbon atoms in which at least one ring is aromatic in nature, for example phenyl, benzyl, naphthyl or indanyl. Preferred is the phenyl group.
The term "heteroaryl" denotes a cyclic aromatic hydrocarbon radical consisting of one or more fused rings containing 5-14 ring atoms, preferably containing 5-10 ring atoms, in which at least one ring is aromatic in nature, and which contains at least one heteroatom, selected from N, 0 or S, for example quinoxalinyl, dihydroisoquinolinyl, pyrazin-2-yl, pyrazol-1-yl, 2,4-dihydro-pyrazol-3-one, pyridinyl, isoxazolyl, benzo[1,3]dioxol, pyridyl, pyrimidin-4-yl, pyrimidin-5-yl, benzotriazol-5-yl, benzoimidazol-5-yl, [1,3,4]-oxadiazol-2-yl, [1,2.4]triazol-1-yl, [1,6]naphthyridin-2-yl, imidazo[4,5-b]pyridine-6-yl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, furyl, imidazol-1-yl, or benzofuranyl. Preferred heteroaryl group is pyridine-2,3or 4-yl.
The term heterocyclyl denotes a five or six membered alkyl ring, wherein one or two carbon atoms are replaced by N, S or 0, for example the following groups:
morpholinyl, 1,1-dioxo-1-6-isothiazolidin-2-yl, piperazinyl, optionally substituted in 1 position by carboxylic acid tert-butyl ester or is 1,1,-dioxo-l-6-thiomorpholin-4-yl.
The term "pharmaceutically acceptable acid addition salts" embraces salts with inorganic and organic acids, such as hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and the like.
Compounds of formula I, wherein Ari is aryl and Ar 2 is phenyl are preferred.
Preferred specific compounds are the followings:
4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -benzonitrile 3- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -benzonitrile 4-({ [(3RS,4SR)- 1-(4-cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amino } -methyl)-2-fluoro-benzonitrile 4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -3 -fluoro-benzonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(2-fluoro-5 -methanesulfonyl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-methanesulfonyl-phenyl)-methanone 4- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl }-2-methyl-benzonitrile 1-(4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine- l -carbonyl} -phenyl)-ethanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-morpholin-4-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4- [1,2,4]triazo 1-1-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-imidazol-l-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-[4-(1,1-dioxo-l-6-isothiazolidin-2-yl)-phenyl]-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-2-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-3 -yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4-pyridin-4-yl-phenyl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(4- [[1,3 ,4]oxadiazol-2-yl-phenyl)-methanone N-(4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl }-phenyl)-acetamide 4- {(3 SR,4RS)-3-(4-chloro-3-fluoro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine- l -carbonyl} -benzonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l-yl}-(4-oxazol-5-yl-phenyl)-methanone or 4- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-pyrrolidine-1-carbonyl} -benzonitrile.
Compounds of formula I, wherein Ari is heteroaryl and Ar 2 is phenyl are further preferred.
Preferred specific compounds are the followings:
benzo [ 1,3 ] dioxol-5-yl- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-methyl-pyridin-3-yl)-methanone 5- {(3 SR,4RS)-3 -(3,4-dichloro -phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine- l -carbonyl} -pyridine-2-carbonitrile {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-morpholin-4-yl-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-fluoro-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-(6-methoxy-pyridin-3-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-pyrazol- l -yl-pyridin-3-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(2-methyl-pyridin-4-yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -(6-hydroxy-pyridin-3 -yl)-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} - [ 1, 6]naphthyridin-2-yl-methanone {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-(2-methoxy-pyrimidin-5-yl)-methanone (3H-benzotriazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl} -methanone (3H-benzoimidazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} -methanone 4-(5- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester or {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- l -yl} - [6-(1, 1 -dioxo- l -6-thiomorpholin-4-yl)-pyridin-3-yl]-methanone.
The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the compounds of the invention are shown in the following schemes. The skills required for carrying out the reaction and purification of the resulting products are known to those skilled in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.
The compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods. Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. The reaction sequence is not limited to the one displayed in the schemes, however, depending on the starting materials and their respective reactivity the sequence of reaction steps can be freely altered. Starting materials are either commercially available or can be prepared by methods analogous to the methods given below, by methods described in references cited in the description or in the examples, or by methods known in the art.
The present compounds of formula I and their pharmaceutically acceptable salts may be prepared by methods, known in the art, for example by the process variants described below, which process comprises a) coupling a compound of formula (R3)P \ / \ Ark (R2)0 N-/
N
H VIII
with a suitable acid chloride or carboxylic acid of formula R-C(O)-Ari-(R')õ
wherein R is Cl or hydroxy, to a compound of formula 3) Ar2 (R2)0 P
,()'IN-/
N
(R1)nAr1 O
wherein the substituents R', R2, R3, Ar', Ar2 and the definitions o, n and p are described above, or b) alkylating a compound of formula (R 3)p N~
O
-,N
N
(R1)Art O
n XII
with a compound of formula Hal-CH2-Are-(R2)0 to a compound of formula 3) Ar2 (R2)0 P / N-/
N
(R1)nAr1 O
wherein the substituents R', R2, R3, Ar', Ar2 and the definitions o, n and p are described above, and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
The preparation of compounds of formula I is further described in more detail in schemes I - II
and in examples 1 -70.
General scheme 1 (R 3 (R3) )P~ P
\ NHz ( 3) / I O SiMe3 NOz R P \ NO2 + N~
N N
Ph III IV ~ Ph V
Ph (R )p \ NH (R3)P \ / NAr2 (RZ) (R3)P \ / N~ar2 (RZ)o N N
PhJ VI PhJ VII VIII
(R3 )P ' N Ar? (RZ) N
(R1)- Ar1~O
The pyrrolidines IV were prepared via a stereo specific 1,3-dipolar cycloaddition between 2-nitrostyrene derivatives II and the azomethine ylide generated in situ from the N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine III in the presence of a catalytic amount of acid, such as TFA. Reduction of the nitro moiety using standard conditions for example SnC12.H20 yielded V. The amino moiety was subsequently methylated in a two step sequence, involving first the preparation of the ethyl carbamate followed by its reduction with borane to produce VI. Reductive amination reaction between VI and an aldehyde yielded VII.
Alternatively, VII could be prepared by alkylation. Selective N-debenzylation was then carried out using several known procedures which are compatible with the substitution patterns of the aromatic rings to afford VIII. Finally derivatives I were prepared via a coupling with an acid chloride or carboxylic acide.
\ NHz ( 3) / I O SiMe3 NOz R P \ NO2 + N~
N N
Ph III IV ~ Ph V
Ph (R )p \ NH (R3)P \ / NAr2 (RZ) (R3)P \ / N~ar2 (RZ)o N N
PhJ VI PhJ VII VIII
(R3 )P ' N Ar? (RZ) N
(R1)- Ar1~O
The pyrrolidines IV were prepared via a stereo specific 1,3-dipolar cycloaddition between 2-nitrostyrene derivatives II and the azomethine ylide generated in situ from the N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine III in the presence of a catalytic amount of acid, such as TFA. Reduction of the nitro moiety using standard conditions for example SnC12.H20 yielded V. The amino moiety was subsequently methylated in a two step sequence, involving first the preparation of the ethyl carbamate followed by its reduction with borane to produce VI. Reductive amination reaction between VI and an aldehyde yielded VII.
Alternatively, VII could be prepared by alkylation. Selective N-debenzylation was then carried out using several known procedures which are compatible with the substitution patterns of the aromatic rings to afford VIII. Finally derivatives I were prepared via a coupling with an acid chloride or carboxylic acide.
General scheme 2`^
(R3)p (R3)p (R3)p (R3)p NH \ / N-Boc N-BOC
\ / N-Boc s N \N \N
Phj VI Ph IX X 1 XI
(R )n Ar 0 (R ) (R3) -- C4-) Ar? (R2)0 NH N
N
(R1)-Ar'~0 XII (R')n Ar' 0 1 Alternatively, the pyrrolidine derivatives I, were also prepared via the route highlighted scheme 2. The secondary amine of the intermediate VI can be BOC-protected to afford IX. Selective N-debenzylation was then carried out using several known procedures which are compatible with the substitution patterns of the aromatic rings to afford X. Standard coupling reaction with an acid chloride or carboxylic acide gave XI, which could then undergo a deprotection with for instance TFA to give XII. The secondary amine was then alkylated via a standard reductive amination or via an alkylation with an alkyl-halide to afford the derivatives I.
Experimental part Abbreviations:
CH2C12 = dichloromethane;
DMAP = dimethylaminopyridine;
HOBt = 1-hydroxy-benzotriazo1 hydrat;
EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
Et3N = triethylamine;
EtOAc = ethyl acetate;
H = hexane;
RT = room temperature;
(R3)p (R3)p (R3)p (R3)p NH \ / N-Boc N-BOC
\ / N-Boc s N \N \N
Phj VI Ph IX X 1 XI
(R )n Ar 0 (R ) (R3) -- C4-) Ar? (R2)0 NH N
N
(R1)-Ar'~0 XII (R')n Ar' 0 1 Alternatively, the pyrrolidine derivatives I, were also prepared via the route highlighted scheme 2. The secondary amine of the intermediate VI can be BOC-protected to afford IX. Selective N-debenzylation was then carried out using several known procedures which are compatible with the substitution patterns of the aromatic rings to afford X. Standard coupling reaction with an acid chloride or carboxylic acide gave XI, which could then undergo a deprotection with for instance TFA to give XII. The secondary amine was then alkylated via a standard reductive amination or via an alkylation with an alkyl-halide to afford the derivatives I.
Experimental part Abbreviations:
CH2C12 = dichloromethane;
DMAP = dimethylaminopyridine;
HOBt = 1-hydroxy-benzotriazo1 hydrat;
EDC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride;
Et3N = triethylamine;
EtOAc = ethyl acetate;
H = hexane;
RT = room temperature;
General procedure I (amide coupling) 3 OH Ra (R Arm R~ ' ( )~ Arm (R 2) (R h N--/ ( )o (R )- Ar O N-~
'~s N
N
H I
VIII (R1)n Art 0 (R3) OH (R3)P
/ N-Boc (R )n Ar O N-Boc ~s N"
N
H XI
X (R1)n Art 0 To a stirred solution of a carboxylic acid derivative (commercially available or known in the literature) (1 mmol) in 10 mL of CH2C12 was added (1.3 mmol) of EDC, (1.3 mmol) of HOBt and Et3N (1.3 mmol). After one hour at RT, was added a pyrrolidine intermediate of general formula (VIII or X). The mixture was stirred at RT over night and then poured onto water and extracted with CH2C12. The combined organic phases were dried over Na2SO4 and concentrated under vacuo. Flash chromatography or preparative HPLC afforded the title compound.
General procedure II
(; ~ 3 (R3)P Arm R~ 1 1 (R )P Arm (R2) (R h N~ ( )o (R )n Ar O N
N
N
H I
VIII (R1)n Art 0 To a stirred solution of a pyrrolidine intermediate VIII (1 mmol) in CH2C12 (15 ml) at RT were added ethyl-diisopropyl-amine (2 mmol) and an acid chloride of formula ArCOCI
(1.1 mmol).
Stirring was continued until completion of the reaction. The reaction mixture was then concentrated under vacuo and purification by flash chromatography on Si02 or preparative HPLC.
'~s N
N
H I
VIII (R1)n Art 0 (R3) OH (R3)P
/ N-Boc (R )n Ar O N-Boc ~s N"
N
H XI
X (R1)n Art 0 To a stirred solution of a carboxylic acid derivative (commercially available or known in the literature) (1 mmol) in 10 mL of CH2C12 was added (1.3 mmol) of EDC, (1.3 mmol) of HOBt and Et3N (1.3 mmol). After one hour at RT, was added a pyrrolidine intermediate of general formula (VIII or X). The mixture was stirred at RT over night and then poured onto water and extracted with CH2C12. The combined organic phases were dried over Na2SO4 and concentrated under vacuo. Flash chromatography or preparative HPLC afforded the title compound.
General procedure II
(; ~ 3 (R3)P Arm R~ 1 1 (R )P Arm (R2) (R h N~ ( )o (R )n Ar O N
N
N
H I
VIII (R1)n Art 0 To a stirred solution of a pyrrolidine intermediate VIII (1 mmol) in CH2C12 (15 ml) at RT were added ethyl-diisopropyl-amine (2 mmol) and an acid chloride of formula ArCOCI
(1.1 mmol).
Stirring was continued until completion of the reaction. The reaction mixture was then concentrated under vacuo and purification by flash chromatography on Si02 or preparative HPLC.
General procedure III (reductive amination) (R)P (R3) / NH N-/ (R2)0 N N
(R), Ar1 O XII (R1)n Art O I
To a stirred solution of a pyrrolidine intermediate XII (1.00 mmol) in MeOH (6 ml)was added the aldehyde (1.20 mmol). Then a solution of NaBH3CN (1.3 mol) in MeOH (1.5 ml) and AcOH
(0.01 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02) or preparative HPLC to afford the desired compound.
As mentioned earlier, the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are antagonists of neurokinin 3 (NK-3) receptors. The compounds were investigated in accordance with the tests given hereinafter.
Experimental procedure The compounds were investigated in accordance with the tests given hereinafter.
[3H] SR142801 competition binding assay hNK3 receptor binding experiment were performed using [3H]SR142801 (Catalog No. TRK1035, specific activity: 74.0 Ci/mmol, Amersham, GE Healthcare UK limited, Buckinghamshire, UK) and membrane isolated from HEK293 cells transiently expressing recombinant human NK3 receptor. After thawing, the membrane homogenates were centrifuged at 48,000 X
g for 10 min at 4 C, the pellets were resuspended in the 50 mM Tris-HC1, 4 mM MnC12, 1 M
phosphoramidon, 0.1 % BSA binding buffer at pH 7.4 to a final assay concentration of 5 g protein/well. For inhibition experiments, membranes were incubated with [3H]SR142801 at a concentration equal to KD value of radio ligand and 10 concentrations of the inhibitory compound (0.0003-10 M) (in a total reaction volume of 500 l) for 75 min at room temperature (RT). At the end of the incubation, membranes were filtered onto unitfilter (96-well white microplate with bonded GF/C filter preincubated 1 h in 0.3% PEI + 0.3% BSA, Packard BioScience, Meriden, CT) with a Filtermate 196 harvester (Packard BioScience) and washed 4 times with ice-cold 50 mM Tris-HC1, pH 7.4 buffer. Nonspecific binding was measured in the presence of 10 M
SB222200 for both radioligands. The radioactivity on the filter was counted (5 min) on a Packard Top-count microplate scintillation counter with quenching correction after addition of 45 gl of microscint 40 (Canberra Packard S.A., Zurich, Switzerland) and shaking for 1 h.
Inhibition curves were fitted according to the Hill equation: y =
l00/(l+(x/ICSO)"H), where nH =
slope factor using Excel-fit 4 software (Microsoft). IC50 values were derived from the inhibition curve and the affinity constant (K;) values were calculated using the Cheng-Prussoff equation K;
= ICSO/(1+[L]/KD) where [L] is the concentration of radioligand and KD is its dissociation constant at the receptor, derived from the saturation isotherm. All experiments were performed in duplicate and the mean standard error (SEM) of the individual K; values was calculated.
Some results of preferred compounds with a hNK-3 receptor affinity <0.05 gM
were shown in the following table 1.
Table 1 Example Data Ki [[tM] Example Data Ki [[tM]
6 0.0209 41 0.0107 9 0.0474 42 0.0335 17 0.0383 43 0.0051 18 0.042 44 0.0056 19 0.0129 45 0.0025 0.0417 47 0.0023 22 0.0302 48 0.0478 23 0.0066 51 0.0146 24 0.0068 57 0.0223 0.0152 59 0.0318 26 0.0148 60 0.0173 27 0.0057 61 0.0373 28 0.0356 63 0.0247 29 0.0084 64 0.002 0.0028 66 0.0126 33 0.0111 67 0.0045 38 0.009 68 0.0146 0.0027 The compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula I and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
Suitable excipients for the manufacture of solutions and syrups are e.g.
water, polyols, saccharose, invert sugar, glucose etc.
Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
(R), Ar1 O XII (R1)n Art O I
To a stirred solution of a pyrrolidine intermediate XII (1.00 mmol) in MeOH (6 ml)was added the aldehyde (1.20 mmol). Then a solution of NaBH3CN (1.3 mol) in MeOH (1.5 ml) and AcOH
(0.01 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02) or preparative HPLC to afford the desired compound.
As mentioned earlier, the compounds of formula I and their pharmaceutically usable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention are antagonists of neurokinin 3 (NK-3) receptors. The compounds were investigated in accordance with the tests given hereinafter.
Experimental procedure The compounds were investigated in accordance with the tests given hereinafter.
[3H] SR142801 competition binding assay hNK3 receptor binding experiment were performed using [3H]SR142801 (Catalog No. TRK1035, specific activity: 74.0 Ci/mmol, Amersham, GE Healthcare UK limited, Buckinghamshire, UK) and membrane isolated from HEK293 cells transiently expressing recombinant human NK3 receptor. After thawing, the membrane homogenates were centrifuged at 48,000 X
g for 10 min at 4 C, the pellets were resuspended in the 50 mM Tris-HC1, 4 mM MnC12, 1 M
phosphoramidon, 0.1 % BSA binding buffer at pH 7.4 to a final assay concentration of 5 g protein/well. For inhibition experiments, membranes were incubated with [3H]SR142801 at a concentration equal to KD value of radio ligand and 10 concentrations of the inhibitory compound (0.0003-10 M) (in a total reaction volume of 500 l) for 75 min at room temperature (RT). At the end of the incubation, membranes were filtered onto unitfilter (96-well white microplate with bonded GF/C filter preincubated 1 h in 0.3% PEI + 0.3% BSA, Packard BioScience, Meriden, CT) with a Filtermate 196 harvester (Packard BioScience) and washed 4 times with ice-cold 50 mM Tris-HC1, pH 7.4 buffer. Nonspecific binding was measured in the presence of 10 M
SB222200 for both radioligands. The radioactivity on the filter was counted (5 min) on a Packard Top-count microplate scintillation counter with quenching correction after addition of 45 gl of microscint 40 (Canberra Packard S.A., Zurich, Switzerland) and shaking for 1 h.
Inhibition curves were fitted according to the Hill equation: y =
l00/(l+(x/ICSO)"H), where nH =
slope factor using Excel-fit 4 software (Microsoft). IC50 values were derived from the inhibition curve and the affinity constant (K;) values were calculated using the Cheng-Prussoff equation K;
= ICSO/(1+[L]/KD) where [L] is the concentration of radioligand and KD is its dissociation constant at the receptor, derived from the saturation isotherm. All experiments were performed in duplicate and the mean standard error (SEM) of the individual K; values was calculated.
Some results of preferred compounds with a hNK-3 receptor affinity <0.05 gM
were shown in the following table 1.
Table 1 Example Data Ki [[tM] Example Data Ki [[tM]
6 0.0209 41 0.0107 9 0.0474 42 0.0335 17 0.0383 43 0.0051 18 0.042 44 0.0056 19 0.0129 45 0.0025 0.0417 47 0.0023 22 0.0302 48 0.0478 23 0.0066 51 0.0146 24 0.0068 57 0.0223 0.0152 59 0.0318 26 0.0148 60 0.0173 27 0.0057 61 0.0373 28 0.0356 63 0.0247 29 0.0084 64 0.002 0.0028 66 0.0126 33 0.0111 67 0.0045 38 0.009 68 0.0146 0.0027 The compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
The administration can, however, also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula I and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi-solid and liquid polyols etc.
Suitable excipients for the manufacture of solutions and syrups are e.g.
water, polyols, saccharose, invert sugar, glucose etc.
Suitable excipients for injection solutions are e.g. water, alcohols, polyols, glycerol, vegetable oils etc.
Suitable excipients for suppositories are e.g. natural or hardened oils, waxes, fats, semi-liquid or liquid polyols etc.
Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
Example A
Tablets of the following composition are manufactured in the usual manner:
mg / tablet Active substance 5 Lactose 45 Corn starch 15 Micro crystalline cellulose 34 Magnesium stearate 1 Tablet weight 100 Example B
Capsules of the following composition are manufactured:
mg / capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5 Capsule fill weight 200 The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelantine capsules.
Example C
Suppositories of the following composition are manufactured:
mg / supp.
Active substance 15 Suppository mass 1285 Total 1300 The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45 C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool, the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
Tablets of the following composition are manufactured in the usual manner:
mg / tablet Active substance 5 Lactose 45 Corn starch 15 Micro crystalline cellulose 34 Magnesium stearate 1 Tablet weight 100 Example B
Capsules of the following composition are manufactured:
mg / capsule Active substance 10 Lactose 155 Corn starch 30 Talc 5 Capsule fill weight 200 The active substance, lactose and corn starch are firstly mixed in a mixer and then in a comminuting machine. The mixture is returned to the mixer, the talc is added thereto and mixed thoroughly. The mixture is filled by machine into hard gelantine capsules.
Example C
Suppositories of the following composition are manufactured:
mg / supp.
Active substance 15 Suppository mass 1285 Total 1300 The suppository mass is melted in a glass or steel vessel, mixed thoroughly and cooled to 45 C. Thereupon, the finely powdered active substance is added thereto and stirred until it has dispersed completely. The mixture is poured into suppository moulds of suitable size, left to cool, the suppositories are then removed from the moulds and packed individually in wax paper or metal foil.
The following Examples illustrate the present invention without limiting it.
All temperatures are given in degrees Celsius.
Process for preparation of pyrrolidine intermediates of formula VIII
PyrrolidineVlll-1 [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
CI / \ F
F
CI
;N
H
a) (3 SR,4RS)-l-Benzyl-3-(3,4-dichloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (1.96 g, 8.2 mmol) in CH2C12 (10 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1,2-dichloro-4-((E)-2-nitro-vinyl)-benzene (1.0 g, 4.58 mmol) and trifluoroacetic acid (52 mg, 4.45 mmol) in CH2C12 (5 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 1.00 g (62 %) of the title compound as a colorless oil. ES-MS m/e:
351.4 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine_(15.0 g, 0.0427 mol) in EtOAc (200 ml) was added portionwise SnC12.2H20 (43.36 g, 0.192 mol). The reaction mixture was then heated at reflux for 4 hours, cooled down to RT and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum gave 9.30 g (75 %) of the title compound as a light yellow oil. The product was then used in the next step without further purification. ES-MS m/e: 321.1 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine (9.2 g, 0.028 mol) in THE (100 ml) was added a solution of K2C03 (7.91 g, 0.057 mol) in H2O
(35 ml). After minutes, ethyl chloroformate (2.86 ml, 0.030 mol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (100 ml) and a solution of borane in THE (1M) was added (114.5 ml). The reaction mixture was then 5 heated at 65 C over night, cooled to RT and carefully quenched with conc.
HC1(100 ml). The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (100 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH 9:1) to afford 7.31 g (76 %) of the title compound as a colorless oil. ES-MS m/e:
335.3 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (3.5 g, 0.010 mol) in MeOH (60 ml)was added 3-fluoro-4-trifluoromethyl-benzaldehyde (2.10 g, 0.0109 mol). Then a solution of NaBH3CN (0.79 g, 0.012 mol) in MeOH
(15 ml) and AcOH (0.1 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 3.31 g (6 2%) of the title compound as a colorless oil.
e) [(3RS,4SR4-(3,4-Dichloro-phenyl pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4trifluoromethyl-benzyl)-methyl-amine (3.30 g, 6.45 mmol) in CH3CN (45 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (1.30 ml, 9.67 mmol). The reaction mixture was stirred at RT
fro 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (10 ml) and zinc dust (1.0 g) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4, concentrated under vacuo to afford 1.43 g (53 %) of the tile compound as a colorless oil. ES-MS m/e: 421.0 (M+H+).
All temperatures are given in degrees Celsius.
Process for preparation of pyrrolidine intermediates of formula VIII
PyrrolidineVlll-1 [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
CI / \ F
F
CI
;N
H
a) (3 SR,4RS)-l-Benzyl-3-(3,4-dichloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (1.96 g, 8.2 mmol) in CH2C12 (10 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1,2-dichloro-4-((E)-2-nitro-vinyl)-benzene (1.0 g, 4.58 mmol) and trifluoroacetic acid (52 mg, 4.45 mmol) in CH2C12 (5 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 1.00 g (62 %) of the title compound as a colorless oil. ES-MS m/e:
351.4 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(3,4-dichloro-phenyl)-4-nitro-pyrrolidine_(15.0 g, 0.0427 mol) in EtOAc (200 ml) was added portionwise SnC12.2H20 (43.36 g, 0.192 mol). The reaction mixture was then heated at reflux for 4 hours, cooled down to RT and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum gave 9.30 g (75 %) of the title compound as a light yellow oil. The product was then used in the next step without further purification. ES-MS m/e: 321.1 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-ylamine (9.2 g, 0.028 mol) in THE (100 ml) was added a solution of K2C03 (7.91 g, 0.057 mol) in H2O
(35 ml). After minutes, ethyl chloroformate (2.86 ml, 0.030 mol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (100 ml) and a solution of borane in THE (1M) was added (114.5 ml). The reaction mixture was then 5 heated at 65 C over night, cooled to RT and carefully quenched with conc.
HC1(100 ml). The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (100 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH 9:1) to afford 7.31 g (76 %) of the title compound as a colorless oil. ES-MS m/e:
335.3 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (3.5 g, 0.010 mol) in MeOH (60 ml)was added 3-fluoro-4-trifluoromethyl-benzaldehyde (2.10 g, 0.0109 mol). Then a solution of NaBH3CN (0.79 g, 0.012 mol) in MeOH
(15 ml) and AcOH (0.1 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 3.31 g (6 2%) of the title compound as a colorless oil.
e) [(3RS,4SR4-(3,4-Dichloro-phenyl pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4trifluoromethyl-benzyl)-methyl-amine (3.30 g, 6.45 mmol) in CH3CN (45 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (1.30 ml, 9.67 mmol). The reaction mixture was stirred at RT
fro 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (10 ml) and zinc dust (1.0 g) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4, concentrated under vacuo to afford 1.43 g (53 %) of the tile compound as a colorless oil. ES-MS m/e: 421.0 (M+H+).
PyrrolidineVlll-2 [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl] -methyl-(4-trifluoromethyl-benzyl)-amine F F
CI / \ F
CI
;N
H
a) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl -amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (0.35 g, 1.04 mmol) in THE (6 ml)was added 1-bromomethyl-4-trifluoromethyl-benzene (0.27 g, 1.15 mmol) and Et3N (0.148 ml, 1.45 mmol). The reaction mixture was stirred overnight at RT and concentrated under vacuo. The product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 130 mg (29 %) of the title compound as a colorless oil. ES-MS
m/e: 492.9 (M+H+).
b) [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl)-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (160 mg, 0.32 mmol) in CH3CN (5 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.070 ml, 0.48 mmol). The reaction mixture was stirred at RT for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (3 ml) and zinc dust (80 mg) was added portion wise over 1 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated under vacuo. The product was purified by column chromatography (CH2C12/ MeOH: 9/1) to afford 85 mg (65 %) of the tile compound as a colorless oil. ES-MS m/e: 403.4 (M+H+).
PyrrolidineVlll-3 [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
CI / \ F
F \ / N F
H
a) (3SR,4RS)-l-Benzyl-3-(4-chloro-3-fluoro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (1.00 g, 4.2 mmol) in CH2C12 (5 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-2-fluoro-4-((E)-2-nitro-vinyl)-benzene (0.68 g, 3.37 mmol) and trifluoroacetic acid (30 ul) in CH2C12 (5 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 0.78 g (55 %) of the title compound as a colorless oil.
ES-MS m/e: 335.2 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(4-chloro-3-fluoro-phenyl)-4-nitro-pyrrolidine (0.78 g, 2.33 mmol) in EtOAc (15 ml) was added portion wise SnC12.2H20 (2.63 g, 11.6 mmol).
The reaction mixture was then heated at reflux for 4 hours, cooled down to RT
and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum. A column chromatography (CH2C12/MeOH 95/5) gave 0.46 g (65 %) of the title compound as a light brown oil. ES-MS m/e: 305.1 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine (0.46 g, 1.51 mmol) in THE (5 ml) was added a solution of K2C03 (0.419 g, 3.0 mmol) in H2O (2 ml).
After 10 minutes, ethyl chloroformate (0.3 ml, 3.0 mmol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (10 ml) and a solution of borane in THE (1M) was added (6.0 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml).
The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (10 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH
9:1) to afford 0.34 g (70 %) of the title compound as a colorless oil. ES-MS m/e: 319.1 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-(3-fluoro-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-methyl-amine (340 mg, 1.06 mmol) in MeOH (6 ml)was added 3-fluoro-4-trifluoromethyl-benzaldehyde (230 mg, 1.20 mmol). Then a solution of NaBH3CN (85 mg, 1.3 mol) in MeOH
(1.5 ml) and AcOH (0.01 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 145 mg (28 %) of the title compound as a colorless oil.
e) [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (145 mg, 0.29 mmol) in CH3CN (2 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.06 ml, 0.44 mmol). The reaction mixture was stirred at RT fro 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (3 ml) and zinc dust (60 mg) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4, concentrated under vacuo to afford 80 mg (67 %) of the tile compound as a colorless oil. ES-MS m/e: 405.3 (M+H+).
PyrrolidineVlll-4 [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
F
F
cl ;N
H
a) (3 SR,4RS)-l-Benzyl-3-(3-chloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (9.69 g, 41 mmol) in CH2C12 (40 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-3-((E)-2-nitro-vinyl)-benzene (0.68 g, 3.37 mmol) and trifluoroacetic acid (0.21 ml) in CH2C12 (40 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 6.30 g (73 %) of the title compound as a colorless oil.
ES-MS m/e: 317.1 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(3-chloro-phenyl)-4-nitro-pyrrolidine (6.30 g, 19.8 mmol) in EtOAc (150 ml) was added portion wise SnC12.2H20 (22.43 g, 99 mmol). The reaction mixture was then heated at reflux for 4 hours, cooled down to RT and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum. A column chromatography (CH2C12/MeOH 95/5) gave 4.47 g (78 %) of the title compound as a light yellow oil. ES-MS m/e: 287.0 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-ylamine (4.47 g, 16.0 mmol) in THE (50 ml) was added a solution of K2C03 (4.31 g, 31 mmol) in H2O
(35 ml). After 10 minutes, ethyl chloroformate (2.97 ml, 31 mmol) was added and stirring was continued at RT
for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (10 ml) and a solution of borane in THE (1M) was added (62 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml).
The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (50 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH
9:1) to afford 2.68 g (57 %) of the title compound as a colorless oil. ES-MS m/e: 301.2 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (2.20 g, 7.31 mmol) in THE (70 ml)was added 4-bromomethyl-2-fluoro-l-trifluoromethyl-benzene (2.25 g, 8.75 mmol) and Et3N (1.21 ml, 8.75 mmol). The reaction mixture was stirred overnight at 40 C, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phase was dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:3) to afford 2.0 g (57 %) of the title compound as a colorless oil.
e) [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (2.0 g, 4.19 mmol) in CH3CN (28 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.85 ml, 6.3 mmol). The reaction mixture was stirred at RT
for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (25 ml) and zinc dust (800 mg) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3.
The organic phase was dried over Na2SO4, concentrated under vacuo to afford 0.90 g (44 %) of the tile compound as a light brown oil. ES-MS m/e: 387.2 (M+H+).
PyrrolidineVlll-5 [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine F F
F
,N
H
a) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl -amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (0.46 g, 1.59 mmol) in THE (15 ml)was added 1-bromomethyl-4-trifluoromethyl-benzene (0.44 g, 1.86 mmo 1) and Et3N (0.155 ml, 1.59 mmo 1). The reaction mixture was stirred overnight at RT
and concentrated under vacuo. The product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 500 mg (71%) of the title compound as a colorless oil. ES-MS
m/e: 459.3 (M+H+).
CI / \ F
CI
;N
H
a) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl -amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (0.35 g, 1.04 mmol) in THE (6 ml)was added 1-bromomethyl-4-trifluoromethyl-benzene (0.27 g, 1.15 mmol) and Et3N (0.148 ml, 1.45 mmol). The reaction mixture was stirred overnight at RT and concentrated under vacuo. The product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 130 mg (29 %) of the title compound as a colorless oil. ES-MS
m/e: 492.9 (M+H+).
b) [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl)-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (160 mg, 0.32 mmol) in CH3CN (5 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.070 ml, 0.48 mmol). The reaction mixture was stirred at RT for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (3 ml) and zinc dust (80 mg) was added portion wise over 1 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated under vacuo. The product was purified by column chromatography (CH2C12/ MeOH: 9/1) to afford 85 mg (65 %) of the tile compound as a colorless oil. ES-MS m/e: 403.4 (M+H+).
PyrrolidineVlll-3 [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
CI / \ F
F \ / N F
H
a) (3SR,4RS)-l-Benzyl-3-(4-chloro-3-fluoro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (1.00 g, 4.2 mmol) in CH2C12 (5 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-2-fluoro-4-((E)-2-nitro-vinyl)-benzene (0.68 g, 3.37 mmol) and trifluoroacetic acid (30 ul) in CH2C12 (5 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 0.78 g (55 %) of the title compound as a colorless oil.
ES-MS m/e: 335.2 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(4-chloro-3-fluoro-phenyl)-4-nitro-pyrrolidine (0.78 g, 2.33 mmol) in EtOAc (15 ml) was added portion wise SnC12.2H20 (2.63 g, 11.6 mmol).
The reaction mixture was then heated at reflux for 4 hours, cooled down to RT
and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum. A column chromatography (CH2C12/MeOH 95/5) gave 0.46 g (65 %) of the title compound as a light brown oil. ES-MS m/e: 305.1 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-ylamine (0.46 g, 1.51 mmol) in THE (5 ml) was added a solution of K2C03 (0.419 g, 3.0 mmol) in H2O (2 ml).
After 10 minutes, ethyl chloroformate (0.3 ml, 3.0 mmol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (10 ml) and a solution of borane in THE (1M) was added (6.0 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml).
The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (10 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH
9:1) to afford 0.34 g (70 %) of the title compound as a colorless oil. ES-MS m/e: 319.1 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-(3-fluoro-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-methyl-amine (340 mg, 1.06 mmol) in MeOH (6 ml)was added 3-fluoro-4-trifluoromethyl-benzaldehyde (230 mg, 1.20 mmol). Then a solution of NaBH3CN (85 mg, 1.3 mol) in MeOH
(1.5 ml) and AcOH (0.01 ml) were added. The reaction mixture was stirred overnight at RT, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 145 mg (28 %) of the title compound as a colorless oil.
e) [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (145 mg, 0.29 mmol) in CH3CN (2 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.06 ml, 0.44 mmol). The reaction mixture was stirred at RT fro 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (3 ml) and zinc dust (60 mg) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4, concentrated under vacuo to afford 80 mg (67 %) of the tile compound as a colorless oil. ES-MS m/e: 405.3 (M+H+).
PyrrolidineVlll-4 [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl] -(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine F F
F
F
cl ;N
H
a) (3 SR,4RS)-l-Benzyl-3-(3-chloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (9.69 g, 41 mmol) in CH2C12 (40 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-3-((E)-2-nitro-vinyl)-benzene (0.68 g, 3.37 mmol) and trifluoroacetic acid (0.21 ml) in CH2C12 (40 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 6.30 g (73 %) of the title compound as a colorless oil.
ES-MS m/e: 317.1 (M+H+).
b) (3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-ylamine To a stirred solution of (3SR,4RS)-l-benzyl-3-(3-chloro-phenyl)-4-nitro-pyrrolidine (6.30 g, 19.8 mmol) in EtOAc (150 ml) was added portion wise SnC12.2H20 (22.43 g, 99 mmol). The reaction mixture was then heated at reflux for 4 hours, cooled down to RT and a saturated aqueous solution of NaHCO3 (500 ml) was added. The salts were filtered off and the product extracted with EtOAc. The organic phases were then dried over Na2SO4, and concentration under vacuum. A column chromatography (CH2C12/MeOH 95/5) gave 4.47 g (78 %) of the title compound as a light yellow oil. ES-MS m/e: 287.0 (M+H+).
c) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-ylamine (4.47 g, 16.0 mmol) in THE (50 ml) was added a solution of K2C03 (4.31 g, 31 mmol) in H2O
(35 ml). After 10 minutes, ethyl chloroformate (2.97 ml, 31 mmol) was added and stirring was continued at RT
for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (10 ml) and a solution of borane in THE (1M) was added (62 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml).
The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (50 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH
9:1) to afford 2.68 g (57 %) of the title compound as a colorless oil. ES-MS m/e: 301.2 (M+H+).
d) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (2.20 g, 7.31 mmol) in THE (70 ml)was added 4-bromomethyl-2-fluoro-l-trifluoromethyl-benzene (2.25 g, 8.75 mmol) and Et3N (1.21 ml, 8.75 mmol). The reaction mixture was stirred overnight at 40 C, concentrated under vacuo, diluted with EtOAc, washed with H20. The organic phase was dried over Na2SO4 and the product purified by flash chromatography (Si02, EtOAc/Heptane 1:3) to afford 2.0 g (57 %) of the title compound as a colorless oil.
e) [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yll-(3-fluoro-4-trifluoromethyl-benzyl -methyl-amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (2.0 g, 4.19 mmol) in CH3CN (28 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.85 ml, 6.3 mmol). The reaction mixture was stirred at RT
for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (25 ml) and zinc dust (800 mg) was added portion wise over 3 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3.
The organic phase was dried over Na2SO4, concentrated under vacuo to afford 0.90 g (44 %) of the tile compound as a light brown oil. ES-MS m/e: 387.2 (M+H+).
PyrrolidineVlll-5 [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine F F
F
,N
H
a) [(3RS,4SR -l-Benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl -amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (0.46 g, 1.59 mmol) in THE (15 ml)was added 1-bromomethyl-4-trifluoromethyl-benzene (0.44 g, 1.86 mmo 1) and Et3N (0.155 ml, 1.59 mmo 1). The reaction mixture was stirred overnight at RT
and concentrated under vacuo. The product purified by flash chromatography (Si02, EtOAc/Heptane 1:4) to afford 500 mg (71%) of the title compound as a colorless oil. ES-MS
m/e: 459.3 (M+H+).
b) [(3RS,4SR)-4-(3-chloro-phenyl)-pyrrolidin-3-yll-methyl-(4-trifluoromethyl-benzyl -amine To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3-chloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (500 mg, 1.09 mmol) in CH3CN (7 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.22 ml, 1.63 mmol). The reaction mixture was stirred at RT for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (5 ml) and zinc dust (200 mg) was added portion wise over 1 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated under vacuo. The product was purified by column chromatography (CH2C12/ MeOH: 9/1) to afford 305 mg (76%) of the tile compound as a colorless oil. ES-MS m/e: 369.2 (M+H+).
Process for preparation of pyrrolidine intermediates of formula XII
PyrrolidineXll-1 [(3SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone N
eo a) (3 SR,4SR -l-Benzyl-3-(4-chloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (6.70 g, 28.2 mmol) in CH2C12 (100 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-4-((E)-2-nitro-vinyl)-benzene (4.97 g, 27.1 mmol) and trifluoroacetic acid (0.31 g, 2.7 mmol) in CH2C12 (150 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 6.75 g (79 %) of the title compound as a colorless oil.
b) (3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine Titanium (IV) chloride (0.36 g, 1.89 mmol) was added drop wise to a suspension of zinc powder (0.25 g, 3.78 mmol) in THE (3 ml). This solution was heated at 68 C for one hour, then cooled to RT before (3SR,4RS)-l-benzyl-3-(4-chloro-phenyl)-4-nitro-pyrrolidine (0.20 g, 0.63 mmol) in THE (2 ml) was added. The reaction mixture was then stirred at reflux over night. The reaction was cooled to RT, diluted with 300 ml of Et20, washed with an aqueous solution of NaHCO3 and the organic phases were dried over Na2SO4. Flash chromatography (Si02, CH2C12/MeOH, 9:1) yielded 0.10 g (57 %) of (3RS,4SR)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine as a light yellow oil.
c) [(3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine (1.86 g, 6.51 mmol) in THE (20 ml) was added a solution of K2C03 (1.80 g, 13.02 mmol) in H2O
(15 ml).
After 10 minutes, ethyl chloroformate (0.68 ml, 7.16 mmol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (20 ml) and a solution of borane in THE (1M) was added (26 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml). The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (100 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH 9:1) to afford 1.51 g (77 %) ofrac-[(3S,4R)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine as a colorless oil.
d) [(3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (2.75 g, 9.14 mmol) in CH2C12 (25 ml) was added Et3N (2.50 ml, 18.2 mmol), DMAP (112 mg, 0.91 mmol) and (Boc)20 (2.39 g, 10.95 mmol). After one hour at RT, the organic phase was washed with H20, then dried over Na2SO4. Column chromatography (Heptane/EtOAc:
3/1) afforded 2.60 g (71 %) of the title compound as a yellow oil. ES-MS m/e: 401.3 (M+H+).
e) [(3RS,4SR)-4-(4-Chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (1.30 g, 3.20 mmol) in toluene (30 ml) at RT, was added 1-chloroethyl chloroformate (0.53 ml, 4.80 mmol). The reaction mixture was stirred at 90 C
Process for preparation of pyrrolidine intermediates of formula XII
PyrrolidineXll-1 [(3SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone N
eo a) (3 SR,4SR -l-Benzyl-3-(4-chloro-phenyl -4-nitro-pyrrolidine A solution of N-(methoxymethyl)-N-(phenylmethyl)-N-(trimethylsilyl)methylamine (6.70 g, 28.2 mmol) in CH2C12 (100 ml) was added drop wise, over a 30 minutes period, to a stirred solution of 1-chloro-4-((E)-2-nitro-vinyl)-benzene (4.97 g, 27.1 mmol) and trifluoroacetic acid (0.31 g, 2.7 mmol) in CH2C12 (150 ml) at 0 C. The ice bath was removed, and the solution was stirred at 25 C for an additional 48 h. It was then concentrated and purification by flash chromatography (Si02, EtOAc/H 1:4) afforded 6.75 g (79 %) of the title compound as a colorless oil.
b) (3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine Titanium (IV) chloride (0.36 g, 1.89 mmol) was added drop wise to a suspension of zinc powder (0.25 g, 3.78 mmol) in THE (3 ml). This solution was heated at 68 C for one hour, then cooled to RT before (3SR,4RS)-l-benzyl-3-(4-chloro-phenyl)-4-nitro-pyrrolidine (0.20 g, 0.63 mmol) in THE (2 ml) was added. The reaction mixture was then stirred at reflux over night. The reaction was cooled to RT, diluted with 300 ml of Et20, washed with an aqueous solution of NaHCO3 and the organic phases were dried over Na2SO4. Flash chromatography (Si02, CH2C12/MeOH, 9:1) yielded 0.10 g (57 %) of (3RS,4SR)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine as a light yellow oil.
c) [(3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-amine To a solution of (3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-ylamine (1.86 g, 6.51 mmol) in THE (20 ml) was added a solution of K2C03 (1.80 g, 13.02 mmol) in H2O
(15 ml).
After 10 minutes, ethyl chloroformate (0.68 ml, 7.16 mmol) was added and stirring was continued at RT for an additional 4 h. The intermediate carbamate was then extracted with Et20, dried over Na2SO4 and concentrated under vacuo to give viscous oil. The oil was taken up in THE (20 ml) and a solution of borane in THE (1M) was added (26 ml). The reaction mixture was then heated at 65 C over night, cooled to RT and carefully quenched with conc. HC1(5 ml). The mixture was then heated at 80 C for 2 h, cooled to RT, concentrated under vacuo, diluted with Et20 (100 ml) and neutralized with an aqueous solution of NaHCO3. The organic phases were dried over Na2SO4 and the product purified by flash chromatography (Si02, CH2C12/MeOH 9:1) to afford 1.51 g (77 %) ofrac-[(3S,4R)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine as a colorless oil.
d) [(3RS,4SR -l-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (2.75 g, 9.14 mmol) in CH2C12 (25 ml) was added Et3N (2.50 ml, 18.2 mmol), DMAP (112 mg, 0.91 mmol) and (Boc)20 (2.39 g, 10.95 mmol). After one hour at RT, the organic phase was washed with H20, then dried over Na2SO4. Column chromatography (Heptane/EtOAc:
3/1) afforded 2.60 g (71 %) of the title compound as a yellow oil. ES-MS m/e: 401.3 (M+H+).
e) [(3RS,4SR)-4-(4-Chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (1.30 g, 3.20 mmol) in toluene (30 ml) at RT, was added 1-chloroethyl chloroformate (0.53 ml, 4.80 mmol). The reaction mixture was stirred at 90 C
overnight and concentrated under vacuo. The residue was dissolved in MeOH (30 ml) and the reaction mixture was heated at 80 C for 2 hours. . The solvent was evaporated and the crude product was directly used in the next step without further purification.
e) [(3RS,4SR -l-Benzoyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester Using the standard amide coupling (general procedure I), 82 mg of the title compound was produce from [(3RS,4SR)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and benzoic acid as a white foam. ES-MS m/e: 415.3 (M+H+).
f) [(3SR,4RS)-3-(4-Chloro-phenyl -4-methylamino-pyrrolidin-1-yll-phenyl-methanone To a stirred solution of [(3RS,4SR)-l-benzoyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (80 mg, 0.19 mmol) in CH2C12 (I ml) was added TFA (0.2 ml). The reaction mixture was stirred at RT for 2 hours, aqueous NaHCO3 was added until pH=8 and the product was extracted with CH2C12. The combined organic phase were dried over Na2SO4.
Concentration under vacuo gave 64 mg (95 %) of the title product as a colorless oil. ES-MS m/e:
315.1 (M+H+).
PyrrolidineXll-2 [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-(3,4,5-trimethoxy-phenyl)-methanone CI
N
O X~O
O
O~
a) [(3RS,4SR4-(4-Chloro-phenyl)-1-(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester Using the standard amide coupling (general procedure I), 75 mg of the title compound was produce from [(3RS,4SR)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and 3,4,5-trimethoxy-benzoic acid as a white foam. ES-MS m/e: 505.3 (M+H+).
e) [(3RS,4SR -l-Benzoyl-4-(4-chloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester Using the standard amide coupling (general procedure I), 82 mg of the title compound was produce from [(3RS,4SR)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and benzoic acid as a white foam. ES-MS m/e: 415.3 (M+H+).
f) [(3SR,4RS)-3-(4-Chloro-phenyl -4-methylamino-pyrrolidin-1-yll-phenyl-methanone To a stirred solution of [(3RS,4SR)-l-benzoyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (80 mg, 0.19 mmol) in CH2C12 (I ml) was added TFA (0.2 ml). The reaction mixture was stirred at RT for 2 hours, aqueous NaHCO3 was added until pH=8 and the product was extracted with CH2C12. The combined organic phase were dried over Na2SO4.
Concentration under vacuo gave 64 mg (95 %) of the title product as a colorless oil. ES-MS m/e:
315.1 (M+H+).
PyrrolidineXll-2 [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-(3,4,5-trimethoxy-phenyl)-methanone CI
N
O X~O
O
O~
a) [(3RS,4SR4-(4-Chloro-phenyl)-1-(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester Using the standard amide coupling (general procedure I), 75 mg of the title compound was produce from [(3RS,4SR)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and 3,4,5-trimethoxy-benzoic acid as a white foam. ES-MS m/e: 505.3 (M+H+).
b) [(3SR,4RS)-3-(4-Chloro-phenyl -4-methylamino-pyrrolidin-1-yll-(3,4,5-trimethoxy-phenyl-methanone To a stirred solution of [(3RS,4SR)-4-(4-chloro-phenyl)-1-(3,4,5-trimethoxy-benzoyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (75 mg, 0.15 mmol) in CH2C12 (1 ml) was added TFA (0.2 ml). The reaction mixture was stirred at RT for 2 hours, aqueous NaHCO3 was added until pH=8 and the product was extracted with CH2C12. The combined organic phase were dried over Na2SO4. Concentration under vacuo gave 62 mg (96 %) of the title product as a colorless oil. ES-MS m/e: 405.4 (M+H+).
PyrrolidineXll-3 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl)-4-methylamino-pyrrolidine-l-carbonyl]-benzonitrile CI
C'~ N
N
O
N i &a) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (1.00 g, 2.98 mmol) in CH2C12 (10 ml) was added Et3N (0.83 ml, 5.96 mmol), DMAP (73 mg, 0.59 mmol) and (Boc)20 (1.43 g, 6.55 mmol). After one hour at RT, the organic phase was washed with H20, then dried over Na2SO4. Column chromatography (Heptane/EtOAc:
3/1) afforded 0.93 g (71 %) of the title compound as a yellow oil. ES-MS m/e: 435.3 (M+H+).
b) [(3R,4S)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (928 mg, 2.13 mmol) in CH3CN (10 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.45 ml, 2.13 mmol). The reaction mixture was stirred at RT for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (5 ml) and zinc dust (400 mg) was added portion wise over 1 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated under vacuo to afford 415 mg (98%) of the tile compound as a light yellow oil. ES-MS m/e: 345.2 (M+H+).
PyrrolidineXll-3 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl)-4-methylamino-pyrrolidine-l-carbonyl]-benzonitrile CI
C'~ N
N
O
N i &a) [(3RS,4SR -l-Benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amine (1.00 g, 2.98 mmol) in CH2C12 (10 ml) was added Et3N (0.83 ml, 5.96 mmol), DMAP (73 mg, 0.59 mmol) and (Boc)20 (1.43 g, 6.55 mmol). After one hour at RT, the organic phase was washed with H20, then dried over Na2SO4. Column chromatography (Heptane/EtOAc:
3/1) afforded 0.93 g (71 %) of the title compound as a yellow oil. ES-MS m/e: 435.3 (M+H+).
b) [(3R,4S)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester To a stirred solution of [(3RS,4SR)-l-benzyl-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (928 mg, 2.13 mmol) in CH3CN (10 ml) at RT, was added 2,2,2-trichloroethyl chloroformate (0.45 ml, 2.13 mmol). The reaction mixture was stirred at RT for 3 hours, concentrated under vacuo. The residue was dissolved in AcOH (5 ml) and zinc dust (400 mg) was added portion wise over 1 hours. The solvent was evaporated, the residue diluted in EtOAc and the organic phase was washed with an aqueous solution of NaHCO3. The organic phase was dried over Na2SO4 and concentrated under vacuo to afford 415 mg (98%) of the tile compound as a light yellow oil. ES-MS m/e: 345.2 (M+H+).
c) [(3RS,4SR)-1-(4-Cyano-benzoyl)-4-(3,4-dichloro-phenyl pyrrolidin-3-yll-methyl-carbamic acid tert-butyl ester Using the standard amide coupling (general procedure I), 414 mg of the title compound was produce from [(3RS,4S)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester and 4-cyano-benzoic acid as a white powder. ES-MS m/e: 474.0 (M+H+).
d) 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl -4-methylamino-pyrrolidine-l-carbonyll-benzonitrile To a stirred solution of [(3RS,4SR)-1-(4-cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (414mg, 0.87 mmol) in CH2C12 (8 ml) was added TFA
(2 ml). The reaction mixture was stirred at RT for 2 hours, aqueous NaHCO3 was added until pH=8 and the product was extracted with CH2Cl2. The combined organic phase were dried over Na2SO4. Concentration under vacuo gave 302 mg (92 %) of the title product as a colorless oil.
ES-MS m/e: 374.1 (M+H+).
Example 1 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3,4-dichloro-benzyl)-methyl-amino] -pyrrolidin- l-yl}-phenyl-methanone ci N
N
eo Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone (XII-1), - Aldehyde: 3,4-Dichloro-benzaldehyde (commercially available), ES-MS m/e: 475.1 (M+H+).
Example 2 {(3 SR,4RS)-3-(4-Chloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- 1-yl}-phenyl-methanone F F
CI F
_ F
N
N
eo Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone (XII-1), - Aldehyde: 3-Fluoro-4-trifluoromethyl-benzaldehyde (commercially available), ES-MS m/e: 491.3 (M+H+).
Example 3 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3,4-dichloro-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(3,4,5-trimethoxy-phenyl)-methanone CI
CI
_ CI
\ N
.\N/
O
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-1-yl]-(3,4,5-trimethoxy-phenyl)-methanone (XII-2), - Aldehyde: 3,4-Dichloro-benzaldehyde (commercially available), ES-MS m/e: 563.2 (M+H+).
Example 4 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3-fuoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,4,5-trimethoxy-phenyl)-methanone F F
CI F
F
O O
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-(3,4,5-trimethoxy-phenyl)-methanone (XII-2), - Aldehyde: 3-Fluoro-4-trifluoromethyl-benzaldehyde (commercially available), ES-MS m/e: 581.2 (M+H+).
Example 5 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-phenyl-methanone F F
F
CI / \ F
CI
.,~N
N
e O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Benzoic acid (commercially available), ES-MS m/e: 525.3 (M+H+).
Example 6 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
CI F
dNe O
"_o N
Coupling according to general procedure II:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Acid chlorid: 4-Cyano-benzoyl chloride (commercially available), ES-MS m/e: 550.3 (M+H+).
Example 7 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2-fluoro-3-trifluoromethyl-phenyl)-methanone F F
CI F
F
CI
N
,d N
O
F
F F
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-3-trifluoromethyl-benzoic acid (commercially available), ES-MS m/e: 611.1 (M+H+).
Example 8 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2,3-difluoro-phenyl)-methanone F F
F
CI / \ F
CI
,dN
N
O
/ F
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2,3-Difluoro-benzoic acid (commercially available), ES-MS m/e: 561.1 (M+H+).
Example 9 3- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
F
CI
.,~N
O
"
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3-Cyano-benzoic acid (commercially available), ES-MS m/e: 550.3 (M+H+).
Example 10 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-trifluoromethoxy-phenyl)-methanone F F
CI F
F
CI
N
F~/F O
O
~
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Trifluoromethoxy-benzoic acid (commercially available), ES-MS m/e: 609.1 (M+H+).
Example 11 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-pyridin-3-yl-methanone F F
CI F
CI F
I'd N
N
O
CN%
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Nicotinic acid (commercially available), ES-MS m/e: 526.2 (M+H+).
Example 12 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(5-methyl-isoxazol-3-yl)-methanone F F
CI F
CI / \ F
N
I'd N
O
O-N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Methyl-isoxazole-3-carboxylic acid (commercially available), ES-MS m/e: 530.1 (M+H+).
Example 13 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-methoxy-phenyl)-methanone F F
CI F
F
CI
N
e O 10 1 Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-benzoic acid (commercially available), ES-MS m/e: 555.2 (M+H+).
Example 14 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-m-tolyl-methanone F F
CI F
F
CI
9Lo Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3-Methyl-benzoic acid (commercially available), ES-MS m/e: 539.3 (M+H+).
Example 15 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,5-dimethoxy-phenyl)-methanone F F
CI F
CI F
I'd N
N
O
1(?"- O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3,5-Dimethoxy-benzoic acid (commercially available), ES-MS m/e: 585.2 (M+H+).
Example 16 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,4-dimethoxy-phenyl)-methanone F F
CI F
CI F
O
O ~
~O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3,4-Dimethoxy-benzoic acid (commercially available), ES-MS m/e: 585.2 (M+H+).
Example 17 Benzo [ 1,3] dioxol-5-yl-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-methanone F F
CI F
F
CI OdN-/
N
(O O
01 ), ~
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Benzo[1,3]dioxole-5-carboxylic acid (commercially available), ES-MS m/e: 569.2 (M+H+).
Example 18 4-({ [(3RS,4SR)-1-(4-Cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl] -methyl-amino}-methyl)-2-fluoro-benzonitrile N
CI
CI
N/
O
i &
N
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl)-4-methylamino-pyrrolidine-1-carbonyl]-benzonitrile (XII-3), - Aldehyde: 2-Fluoro-4-formyl-benzonitrile (commercially available), ES-MS m/e: 506.9 (M+H+).
Example 19 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-3-fluoro-benzonitrile F F
CI F
F
CI
N
dNO
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Cyano-2-fluoro-benzoic acid (commercially available), ES-MS m/e: 568.1 (M+H+).
Example 20 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-fluoro-5-methanesulfonyl-phenyl)-methanone F F
CI F
F
CI
O N
O
I ~'F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-5-methanesulfonyl-benzoic acid (described in the patent US20060149062), ES-MS m/e: 621.1 (M+H+).
Example 21 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(5-ethanesulfonyl-2-fluoro-phenyl)-methanone F F
CI F
F
CI
N
\N/
~SO
O
O
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Ethanesulfonyl-2-fluoro-benzoic acid (described in the patent W02006072436), ES-MS m/e: 635.1 (M+H+).
Example 22 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-methanesulfonyl-phenyl)-methanone F F
CI F
F
CI
N
O
os I /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methanesulfonyl-benzoic acid (commercially available), ES-MS m/e: 603.1 (M+H+).
Example 23 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-2-methyl-benzonitrile F F
CI F
F
CI
N
N
I~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Cyano-3-methyl-benzoic acid (preparation described in Bioorg. Med./
Chem. Lett. 14 (2004) 4585-4589), ES-MS m/e: 566.1 (M+H+).
Example 24 1-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-phenyl)-ethanone F F
CI F
CI F
N
eO
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Acetyl-benzoic acid (commercially available), ES-MS m/e: 567.2 (M+H+).
Example 25 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-methyl-pyridin-3-yl)-methanone F F
CI F
CI F
I'd N
N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methyl-nicotinic acid (commercially available), ES-MS m/e: 540.1 (M+H+).
Example 26 5- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridine-2-carbonitrile F F
CI F
CI F
N
O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Cyano-nicotinic acid (commercially available), ES-MS m/e: 551.1 (M+H+).
Example 27 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
N
N
% O
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Morpholin-4-yl-nicotinic acid (commercially available), ES-MS m/e: 611.2 (M+H+).
Example 28 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-fluo ro-pyridin-3-yl)-methanone F F
CI / \ F
F
CI ON--"
N
% O
F N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Fluoro-nicotinic acid (commercially available), ES-MS m/e: 546.2 (M+H+).
Example 29 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(6-methoxy-pyridin-3-yl)-methanone F F
CI F
F
CI
N
O
o IN
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methoxy-nicotinic acid (commercially available), ES-MS m/e: 556.1 (M+H+).
Example 30 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-pyrazol- l-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
NN
% O
CN' N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Pyrazol-1-yl-nicotinic acid (commercially available), ES-MS m/e: 592.1 (M+H+).
Example 31 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-p-tolyl-methanone F F
CI F
CI F
I'd N
N
O
,,e Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methyl-benzoic acid (commercially available), ES-MS m/e: 539.2 (M+H+).
Example 32 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-morpholin-4-yl-pyridin-4-yl)-methanone F F
CI F
CI \ F
N
O
N
CND
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Morpholin-4-yl-isonicotinic acid (commercially available), ES-MS m/e: 611.2 (M+H+).
Example 33 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methyl-pyridin-4-yl)-methanone F F
CI F
F
CI
N
,d N
O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methyl-isonicotinic acid (commercially available), ES-MS m/e: 542.2 (M+H+).
Example 34 N-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-acetamide F F
CI F
F
CI
O
N /
O\/N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Acetylamino-isonicotinic acid (commercially available), ES-MS m/e: 583.2 (M+H+).
Example 35 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methoxy-pyridin-4-yl)-methanone F F
CI F
CI F
I'd N
N
O
N /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-isonicotinic acid (commercially available), ES-MS m/e: 556.2 (M+H+).
Example 36 (4-Chloro-phenyl)-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI / \ F
F
CI ON--"
N
e O
CI
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Chloro-benzoic acid (commercially available), ES-MS m/e: 561.1 (M+H+).
Example 37 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2-fluoro-5-methyl-phenyl)-methanone F F
CI F
F
CI
N
F N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-5-methyl-benzoic acid (commercially available), ES-MS m/e: 557.1 (M+H+).
Example 38 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-morpholin-4-yl-phenyl)-methanone F F
CI F
CI F
N
~ O
rN /
OJ
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Morpholin-4-yl-benzoic acid (commercially available), ES-MS m/e: 609.6 (M+H+).
Example 39 2-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl}-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one F F
CI F
F
CI N
N
O O
-N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(3-Methyl-5-oxo-4,5-dihydro-pyrazo1-1-yl)-benzoic acid (commercially available), ES-MS m/e: 620.7 (M+H+).
Example 40 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-[1,2,4]triazol-1-yl-phenyl)-methanone F F
CI F
CI F
NN
~ O
N ''N /
\-- N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-[1,2,4]Triazol-1-yl-benzoic acid (commercially available), ES-MS m/e: 591.8 (M+H+).
Example 41 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone F F
CI F
F
CI
N
NN
~ O
NON /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Imidazol-1-yl-benzoic acid (commercially available), ES-MS m/e: 590.8 (M+H+).
Example 42 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-[4-(1,1-dioxo-1-6-isothiazolidin-2-yl)-phenyl]-methanone F F
CI F
CI F
NN
\ LO
OS\O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(1,1-Dioxo-l-6-isothiazolidin-2-yl)-benzoic acid (commercially available), ES-MS m/e: 643.8 (M+H+).
Example 43 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-2-yl-phenyl)-methanone F F
CI F
F
CI
N
N
O
iN
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-2-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 44 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-3-yl-phenyl)-methanone F F
CI F
F
CI
\ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-3-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 45 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-4-yl-phenyl)-methanone F F
CI F
F
CI
N
N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-4-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 46 (6-Amino-pyridin-3-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
% O
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Amino-nicotinic acid (commercially available), ES-MS m/e: 540.8 (M+H+).
Example 47 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-[1,3,4] oxadiazol-2-yl-phenyl)-methanone F F
CI F
F
CI
N
N
~ O
N I /
N\~_ O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-[1,3,4]Oxadiazol-2-yl-benzoic acid (commercially available), ES-MS m/e: 592.9 (M+H+).
Example 48 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(6-hydroxy-pyridin-3-yl)-methanone F F
CI F
CI F
N
% O
I N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Hydroxy-nicotinic acid (commercially available), ES-MS m/e: 542.1 (M+H+).
Example 49 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-hydroxy-pyridin-4-yl)-methanone F F
F
CI / \ F
CI
.,~N
N
y O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Hydroxy-isonicotinic acid (commercially available), ES-MS m/e: 542.1 (M+H+).
Example 50 (5-Amino-pyridin-2-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
&NO
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Amino-pyridine-2-carboxylic acid (commercially available), ES-MS m/e: 541.2 (M+H+).
Example 51 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-[1,6] naphthyridin-2-yl-methanone F F
CI F
F
CI
N
N
a,, No III 10 /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: [1,6]Naphthyridine-2-carboxylic acid (commercially available), ES-MS m/e: 577.4 (M+H+).
Example 52 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-pyrimidin-4-yl-methanone F F
F
CI / \ F
CI
,dN
N
ki o Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Pyrimidine-4-carboxylic acid (commercially available), ES-MS m/e: 527.3 (M+H+).
Example 53 (2-Amino-5-chloro-pyrimidin-4-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
I'd N
N
N 10 ~NIII / CI
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Amino-5-chloro-pyrimidine-4-carboxylic acid (commercially available), ES-MS m/e: 576.8 (M+H+).
Example 54 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-pyrazin-2-yl-methanone F F
CI F
CI \ F
N
CN' N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 527.3 (M+H+).
Example 55 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(5-methyl-pyrazin-2-yl)-methanone F F
CI F
CI F
I'd N
N
~N\ o Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Methyl-pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 541.4 (M+H+).
Example 56 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-methoxy-pyrazin-2-yl)-methanone F F
CI F
CI F
1~O_~N\
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methoxy-pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 557.4 (M+H+).
Example 57 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methoxy-pyrimidin-5-yl)-methanone F F
F
CI / \ F
CI
.,~N
N o I
O N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-pyrimidine-5-carboxylic acid (commercially available), ES-MS m/e: 557.4 (M+H+).
Example 58 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-methylamino-phenyl)-methanone F F
F
CI / \ F
CI
N
O
N /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methylamino-benzoic acid (commercially available), ES-MS m/e: 554.4 (M+H+).
Example 59 (3H-Benzotriazol-5-yl)-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
F
CI
N
O
N
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Benzotriazole-5-carboxylic acid (commercially available), ES-MS m/e: 566.4 (M+H+).
Example 60 (3H-Benzoimidazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichlo ro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
N
O
N
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Benzoimidazole-5-carboxylic acid (commercially available), ES-MS m/e: 564.4 (M+H+).
Example 61 N-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-phenyl)-acetamide F F
CI F
F
CI
N
N
p I O
AN &
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Acetylamino-benzoic acid (commercially available), ES-MS m/e: 582.4 (M+H+).
Example 62 {(3 S,4R)-3-(3,4-Dichlo ro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(3H-imidazo [4,5-b] pyridin-6-yl)-methanone F F
CI F
CI F
N
N
o N
P--\--N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid (commercially available), ES-MS m/e: 566.4 (M+H+).
Example 63 4-(5-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester F F
CI F
F
CI / \ \N-/
.,~N o N
O Y
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(5-Carboxy-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (commercially available), ES-MS m/e: 710.4 (M+H+).
Example 64 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-[6-(1,1-dioxo-l-6-thiomorpholin-4-yl)-pyridin-3-yl]-methanone F F
CI F
CI F
N
o N
011 r Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-(1,l-Dioxo-1-6-thiomorpholin-4-yl)-nicotinic acid (commercially available), ES-MS m/e: 659.5 (M+H+).
Example 65 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-piperazin- l-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
N
N
N o N I /
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Piperazin-1-yl-nicotinic acid (commercially available), ES-MS m/e: 610.5 (M+H+).
Example 66 4-{(3 SR,4RS)-3-(4-Chloro-3-fluoro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
F ~ D F
&O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-3), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 533.8 (M+H+).
Example 67 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-oxazol-5-yl-phenyl)-methanone F F
CI F
F
CI
N
N
cr00 Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Oxazol-5-yl-benzoic acid (commercially available), ES-MS m/e: 592.3 (M+H+).
Example 68 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [methyl-(4-trifluo ro methyl-benzyl)-amino] -pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
CI
N
~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (VIII-2), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 531.8 (M+H+).
Example 69 4- {(3 SR,4RS)-3-(3-Chlo ro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl}-benzonitrile F F
F
F
CI
N
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-4), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 516.0 (M+H+).
Example 70 4-{(3 SR,4RS)-3-(3-Chloro-phenyl)-4- [methyl-(4-trifluoromethyl-benzyl)-amino]
-pyrrolidine-l-carbonyl}-benzonitrile F F
F
CI
N
~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (VIII-5), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 498.0 (M+H+).
d) 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl -4-methylamino-pyrrolidine-l-carbonyll-benzonitrile To a stirred solution of [(3RS,4SR)-1-(4-cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-carbamic acid tert-butyl ester (414mg, 0.87 mmol) in CH2C12 (8 ml) was added TFA
(2 ml). The reaction mixture was stirred at RT for 2 hours, aqueous NaHCO3 was added until pH=8 and the product was extracted with CH2Cl2. The combined organic phase were dried over Na2SO4. Concentration under vacuo gave 302 mg (92 %) of the title product as a colorless oil.
ES-MS m/e: 374.1 (M+H+).
Example 1 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3,4-dichloro-benzyl)-methyl-amino] -pyrrolidin- l-yl}-phenyl-methanone ci N
N
eo Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone (XII-1), - Aldehyde: 3,4-Dichloro-benzaldehyde (commercially available), ES-MS m/e: 475.1 (M+H+).
Example 2 {(3 SR,4RS)-3-(4-Chloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin- 1-yl}-phenyl-methanone F F
CI F
_ F
N
N
eo Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-phenyl-methanone (XII-1), - Aldehyde: 3-Fluoro-4-trifluoromethyl-benzaldehyde (commercially available), ES-MS m/e: 491.3 (M+H+).
Example 3 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3,4-dichloro-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(3,4,5-trimethoxy-phenyl)-methanone CI
CI
_ CI
\ N
.\N/
O
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-1-yl]-(3,4,5-trimethoxy-phenyl)-methanone (XII-2), - Aldehyde: 3,4-Dichloro-benzaldehyde (commercially available), ES-MS m/e: 563.2 (M+H+).
Example 4 {(3 SR,4RS)-3-(4-C hloro-phenyl)-4- [(3-fuoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,4,5-trimethoxy-phenyl)-methanone F F
CI F
F
O O
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: [(3 SR,4RS)-3-(4-Chloro-phenyl)-4-methylamino-pyrrolidin-l-yl]-(3,4,5-trimethoxy-phenyl)-methanone (XII-2), - Aldehyde: 3-Fluoro-4-trifluoromethyl-benzaldehyde (commercially available), ES-MS m/e: 581.2 (M+H+).
Example 5 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-phenyl-methanone F F
F
CI / \ F
CI
.,~N
N
e O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Benzoic acid (commercially available), ES-MS m/e: 525.3 (M+H+).
Example 6 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
CI F
dNe O
"_o N
Coupling according to general procedure II:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Acid chlorid: 4-Cyano-benzoyl chloride (commercially available), ES-MS m/e: 550.3 (M+H+).
Example 7 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2-fluoro-3-trifluoromethyl-phenyl)-methanone F F
CI F
F
CI
N
,d N
O
F
F F
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-3-trifluoromethyl-benzoic acid (commercially available), ES-MS m/e: 611.1 (M+H+).
Example 8 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2,3-difluoro-phenyl)-methanone F F
F
CI / \ F
CI
,dN
N
O
/ F
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2,3-Difluoro-benzoic acid (commercially available), ES-MS m/e: 561.1 (M+H+).
Example 9 3- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
F
CI
.,~N
O
"
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3-Cyano-benzoic acid (commercially available), ES-MS m/e: 550.3 (M+H+).
Example 10 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-trifluoromethoxy-phenyl)-methanone F F
CI F
F
CI
N
F~/F O
O
~
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Trifluoromethoxy-benzoic acid (commercially available), ES-MS m/e: 609.1 (M+H+).
Example 11 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-pyridin-3-yl-methanone F F
CI F
CI F
I'd N
N
O
CN%
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Nicotinic acid (commercially available), ES-MS m/e: 526.2 (M+H+).
Example 12 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(5-methyl-isoxazol-3-yl)-methanone F F
CI F
CI / \ F
N
I'd N
O
O-N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Methyl-isoxazole-3-carboxylic acid (commercially available), ES-MS m/e: 530.1 (M+H+).
Example 13 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-methoxy-phenyl)-methanone F F
CI F
F
CI
N
e O 10 1 Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-benzoic acid (commercially available), ES-MS m/e: 555.2 (M+H+).
Example 14 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-m-tolyl-methanone F F
CI F
F
CI
9Lo Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3-Methyl-benzoic acid (commercially available), ES-MS m/e: 539.3 (M+H+).
Example 15 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,5-dimethoxy-phenyl)-methanone F F
CI F
CI F
I'd N
N
O
1(?"- O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3,5-Dimethoxy-benzoic acid (commercially available), ES-MS m/e: 585.2 (M+H+).
Example 16 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(3,4-dimethoxy-phenyl)-methanone F F
CI F
CI F
O
O ~
~O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3,4-Dimethoxy-benzoic acid (commercially available), ES-MS m/e: 585.2 (M+H+).
Example 17 Benzo [ 1,3] dioxol-5-yl-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-methanone F F
CI F
F
CI OdN-/
N
(O O
01 ), ~
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Benzo[1,3]dioxole-5-carboxylic acid (commercially available), ES-MS m/e: 569.2 (M+H+).
Example 18 4-({ [(3RS,4SR)-1-(4-Cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl] -methyl-amino}-methyl)-2-fluoro-benzonitrile N
CI
CI
N/
O
i &
N
Reductive amination according to general procedure III:
- Pyrrolidine intermediate: 4-[(3SR,4RS)-3-(3,4-Dichloro-phenyl)-4-methylamino-pyrrolidine-1-carbonyl]-benzonitrile (XII-3), - Aldehyde: 2-Fluoro-4-formyl-benzonitrile (commercially available), ES-MS m/e: 506.9 (M+H+).
Example 19 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-3-fluoro-benzonitrile F F
CI F
F
CI
N
dNO
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Cyano-2-fluoro-benzoic acid (commercially available), ES-MS m/e: 568.1 (M+H+).
Example 20 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-fluoro-5-methanesulfonyl-phenyl)-methanone F F
CI F
F
CI
O N
O
I ~'F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-5-methanesulfonyl-benzoic acid (described in the patent US20060149062), ES-MS m/e: 621.1 (M+H+).
Example 21 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(5-ethanesulfonyl-2-fluoro-phenyl)-methanone F F
CI F
F
CI
N
\N/
~SO
O
O
F
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Ethanesulfonyl-2-fluoro-benzoic acid (described in the patent W02006072436), ES-MS m/e: 635.1 (M+H+).
Example 22 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-methanesulfonyl-phenyl)-methanone F F
CI F
F
CI
N
O
os I /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methanesulfonyl-benzoic acid (commercially available), ES-MS m/e: 603.1 (M+H+).
Example 23 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-2-methyl-benzonitrile F F
CI F
F
CI
N
N
I~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Cyano-3-methyl-benzoic acid (preparation described in Bioorg. Med./
Chem. Lett. 14 (2004) 4585-4589), ES-MS m/e: 566.1 (M+H+).
Example 24 1-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-phenyl)-ethanone F F
CI F
CI F
N
eO
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Acetyl-benzoic acid (commercially available), ES-MS m/e: 567.2 (M+H+).
Example 25 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-methyl-pyridin-3-yl)-methanone F F
CI F
CI F
I'd N
N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methyl-nicotinic acid (commercially available), ES-MS m/e: 540.1 (M+H+).
Example 26 5- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridine-2-carbonitrile F F
CI F
CI F
N
O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Cyano-nicotinic acid (commercially available), ES-MS m/e: 551.1 (M+H+).
Example 27 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
N
N
% O
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Morpholin-4-yl-nicotinic acid (commercially available), ES-MS m/e: 611.2 (M+H+).
Example 28 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-fluo ro-pyridin-3-yl)-methanone F F
CI / \ F
F
CI ON--"
N
% O
F N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Fluoro-nicotinic acid (commercially available), ES-MS m/e: 546.2 (M+H+).
Example 29 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(6-methoxy-pyridin-3-yl)-methanone F F
CI F
F
CI
N
O
o IN
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methoxy-nicotinic acid (commercially available), ES-MS m/e: 556.1 (M+H+).
Example 30 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-pyrazol- l-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
NN
% O
CN' N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Pyrazol-1-yl-nicotinic acid (commercially available), ES-MS m/e: 592.1 (M+H+).
Example 31 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-p-tolyl-methanone F F
CI F
CI F
I'd N
N
O
,,e Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methyl-benzoic acid (commercially available), ES-MS m/e: 539.2 (M+H+).
Example 32 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(2-morpholin-4-yl-pyridin-4-yl)-methanone F F
CI F
CI \ F
N
O
N
CND
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Morpholin-4-yl-isonicotinic acid (commercially available), ES-MS m/e: 611.2 (M+H+).
Example 33 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methyl-pyridin-4-yl)-methanone F F
CI F
F
CI
N
,d N
O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methyl-isonicotinic acid (commercially available), ES-MS m/e: 542.2 (M+H+).
Example 34 N-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-acetamide F F
CI F
F
CI
O
N /
O\/N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Acetylamino-isonicotinic acid (commercially available), ES-MS m/e: 583.2 (M+H+).
Example 35 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methoxy-pyridin-4-yl)-methanone F F
CI F
CI F
I'd N
N
O
N /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-isonicotinic acid (commercially available), ES-MS m/e: 556.2 (M+H+).
Example 36 (4-Chloro-phenyl)-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI / \ F
F
CI ON--"
N
e O
CI
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Chloro-benzoic acid (commercially available), ES-MS m/e: 561.1 (M+H+).
Example 37 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(2-fluoro-5-methyl-phenyl)-methanone F F
CI F
F
CI
N
F N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Fluoro-5-methyl-benzoic acid (commercially available), ES-MS m/e: 557.1 (M+H+).
Example 38 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-morpholin-4-yl-phenyl)-methanone F F
CI F
CI F
N
~ O
rN /
OJ
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Morpholin-4-yl-benzoic acid (commercially available), ES-MS m/e: 609.6 (M+H+).
Example 39 2-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl}-phenyl)-5-methyl-2,4-dihydro-pyrazol-3-one F F
CI F
F
CI N
N
O O
-N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(3-Methyl-5-oxo-4,5-dihydro-pyrazo1-1-yl)-benzoic acid (commercially available), ES-MS m/e: 620.7 (M+H+).
Example 40 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-[1,2,4]triazol-1-yl-phenyl)-methanone F F
CI F
CI F
NN
~ O
N ''N /
\-- N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-[1,2,4]Triazol-1-yl-benzoic acid (commercially available), ES-MS m/e: 591.8 (M+H+).
Example 41 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone F F
CI F
F
CI
N
NN
~ O
NON /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Imidazol-1-yl-benzoic acid (commercially available), ES-MS m/e: 590.8 (M+H+).
Example 42 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-[4-(1,1-dioxo-1-6-isothiazolidin-2-yl)-phenyl]-methanone F F
CI F
CI F
NN
\ LO
OS\O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(1,1-Dioxo-l-6-isothiazolidin-2-yl)-benzoic acid (commercially available), ES-MS m/e: 643.8 (M+H+).
Example 43 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-2-yl-phenyl)-methanone F F
CI F
F
CI
N
N
O
iN
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-2-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 44 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-3-yl-phenyl)-methanone F F
CI F
F
CI
\ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-3-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 45 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-pyridin-4-yl-phenyl)-methanone F F
CI F
F
CI
N
N
O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Pyridin-4-yl-benzoic acid (commercially available), ES-MS m/e: 601.8 (M+H+).
Example 46 (6-Amino-pyridin-3-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
% O
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Amino-nicotinic acid (commercially available), ES-MS m/e: 540.8 (M+H+).
Example 47 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(4-[1,3,4] oxadiazol-2-yl-phenyl)-methanone F F
CI F
F
CI
N
N
~ O
N I /
N\~_ O
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-[1,3,4]Oxadiazol-2-yl-benzoic acid (commercially available), ES-MS m/e: 592.9 (M+H+).
Example 48 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-(6-hydroxy-pyridin-3-yl)-methanone F F
CI F
CI F
N
% O
I N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Hydroxy-nicotinic acid (commercially available), ES-MS m/e: 542.1 (M+H+).
Example 49 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-hydroxy-pyridin-4-yl)-methanone F F
F
CI / \ F
CI
.,~N
N
y O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Hydroxy-isonicotinic acid (commercially available), ES-MS m/e: 542.1 (M+H+).
Example 50 (5-Amino-pyridin-2-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
&NO
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Amino-pyridine-2-carboxylic acid (commercially available), ES-MS m/e: 541.2 (M+H+).
Example 51 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-[1,6] naphthyridin-2-yl-methanone F F
CI F
F
CI
N
N
a,, No III 10 /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: [1,6]Naphthyridine-2-carboxylic acid (commercially available), ES-MS m/e: 577.4 (M+H+).
Example 52 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-1-yl}-pyrimidin-4-yl-methanone F F
F
CI / \ F
CI
,dN
N
ki o Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Pyrimidine-4-carboxylic acid (commercially available), ES-MS m/e: 527.3 (M+H+).
Example 53 (2-Amino-5-chloro-pyrimidin-4-yl)- {(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
I'd N
N
N 10 ~NIII / CI
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Amino-5-chloro-pyrimidine-4-carboxylic acid (commercially available), ES-MS m/e: 576.8 (M+H+).
Example 54 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-pyrazin-2-yl-methanone F F
CI F
CI \ F
N
CN' N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: Pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 527.3 (M+H+).
Example 55 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(5-methyl-pyrazin-2-yl)-methanone F F
CI F
CI F
I'd N
N
~N\ o Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 5-Methyl-pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 541.4 (M+H+).
Example 56 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-methoxy-pyrazin-2-yl)-methanone F F
CI F
CI F
1~O_~N\
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Methoxy-pyrazine-2-carboxylic acid (commercially available), ES-MS m/e: 557.4 (M+H+).
Example 57 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(2-methoxy-pyrimidin-5-yl)-methanone F F
F
CI / \ F
CI
.,~N
N o I
O N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 2-Methoxy-pyrimidine-5-carboxylic acid (commercially available), ES-MS m/e: 557.4 (M+H+).
Example 58 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(4-methylamino-phenyl)-methanone F F
F
CI / \ F
CI
N
O
N /
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Methylamino-benzoic acid (commercially available), ES-MS m/e: 554.4 (M+H+).
Example 59 (3H-Benzotriazol-5-yl)-{(3 SR,4RS)-3-(3,4-dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
F
CI
N
O
N
N N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Benzotriazole-5-carboxylic acid (commercially available), ES-MS m/e: 566.4 (M+H+).
Example 60 (3H-Benzoimidazol-5-yl)- {(3 SR,4RS)-3-(3,4-dichlo ro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-l-yl}-methanone F F
CI F
CI F
N
N
O
N
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Benzoimidazole-5-carboxylic acid (commercially available), ES-MS m/e: 564.4 (M+H+).
Example 61 N-(4-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-phenyl)-acetamide F F
CI F
F
CI
N
N
p I O
AN &
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Acetylamino-benzoic acid (commercially available), ES-MS m/e: 582.4 (M+H+).
Example 62 {(3 S,4R)-3-(3,4-Dichlo ro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-(3H-imidazo [4,5-b] pyridin-6-yl)-methanone F F
CI F
CI F
N
N
o N
P--\--N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 3H-Imidazo[4,5-b]pyridine-6-carboxylic acid (commercially available), ES-MS m/e: 566.4 (M+H+).
Example 63 4-(5-{(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-pyridin-2-yl)-piperazine-l-carboxylic acid tert-butyl ester F F
CI F
F
CI / \ \N-/
.,~N o N
O Y
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-(5-Carboxy-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester (commercially available), ES-MS m/e: 710.4 (M+H+).
Example 64 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluoromethyl-benzyl)-methyl-amino] -pyrrolidin-l-yl}-[6-(1,1-dioxo-l-6-thiomorpholin-4-yl)-pyridin-3-yl]-methanone F F
CI F
CI F
N
o N
011 r Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-(1,l-Dioxo-1-6-thiomorpholin-4-yl)-nicotinic acid (commercially available), ES-MS m/e: 659.5 (M+H+).
Example 65 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(6-piperazin- l-yl-pyridin-3-yl)-methanone F F
CI F
F
CI
N
N
N o N I /
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 6-Piperazin-1-yl-nicotinic acid (commercially available), ES-MS m/e: 610.5 (M+H+).
Example 66 4-{(3 SR,4RS)-3-(4-Chloro-3-fluoro-phenyl)-4- [(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
F ~ D F
&O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(4-Chloro-3-fluoro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-3), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 533.8 (M+H+).
Example 67 {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [(3-fluo ro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidin- l-yl}-(4-oxazol-5-yl-phenyl)-methanone F F
CI F
F
CI
N
N
cr00 Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-1), - Carboxylic acid: 4-Oxazol-5-yl-benzoic acid (commercially available), ES-MS m/e: 592.3 (M+H+).
Example 68 4- {(3 SR,4RS)-3-(3,4-Dichloro-phenyl)-4- [methyl-(4-trifluo ro methyl-benzyl)-amino] -pyrrolidine-l-carbonyl}-benzonitrile F F
CI F
CI
N
~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3,4-Dichloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (VIII-2), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 531.8 (M+H+).
Example 69 4- {(3 SR,4RS)-3-(3-Chlo ro-phenyl)-4- [(3-fluoro-4-trifluo romethyl-benzyl)-methyl-amino] -pyrrolidine-l-carbonyl}-benzonitrile F F
F
F
CI
N
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amine (VIII-4), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 516.0 (M+H+).
Example 70 4-{(3 SR,4RS)-3-(3-Chloro-phenyl)-4- [methyl-(4-trifluoromethyl-benzyl)-amino]
-pyrrolidine-l-carbonyl}-benzonitrile F F
F
CI
N
~ O
N
Amide coupling according to general procedure I:
- Pyrrolidine intermediate: [(3RS,4SR)-4-(3-Chloro-phenyl)-pyrrolidin-3-yl]-methyl-(4-trifluoromethyl-benzyl)-amine (VIII-5), - Carboxylic acid: 4-Cyano-benzoic acid (commercially available), ES-MS m/e: 498.0 (M+H+).
Claims (10)
1. A compound of general formula I
wherein Ar1 is phenyl or heteroaryl;
Ar2 is phenyl or heteroaryl;
R1 is hydrogen, halogen, hydroxy, C1-8-alkyl, C1-8-alkoxy, C1-8-alkyl substituted by halogen, C1-8-alkoxy substituted by halogen, S-C1-8-alkyl, -S(O)2- C1-8-alkyl, -S(O)2-di-C1-8-alkyl amino, cyano, amino, mono or di-C1-8-alkyl amino, C(O)-C1-alkyl, NHC(O)-C1-8-alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by C1-8-alkyl;
R2 is hydrogen, halogen,I C1-8-alkyl, C1-8-alkoxy, C1-8-alkyl substituted by halogen or cyano;
R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen;
n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different;
o is 1, 2 or 3; in case o is 2 or 3, R2 way be the same or different;
p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different;
or a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof.
wherein Ar1 is phenyl or heteroaryl;
Ar2 is phenyl or heteroaryl;
R1 is hydrogen, halogen, hydroxy, C1-8-alkyl, C1-8-alkoxy, C1-8-alkyl substituted by halogen, C1-8-alkoxy substituted by halogen, S-C1-8-alkyl, -S(O)2- C1-8-alkyl, -S(O)2-di-C1-8-alkyl amino, cyano, amino, mono or di-C1-8-alkyl amino, C(O)-C1-alkyl, NHC(O)-C1-8-alkyl, cycloalkyl, heterocyclyl, or is heteroaryl, optionally substituted by C1-8-alkyl;
R2 is hydrogen, halogen,I C1-8-alkyl, C1-8-alkoxy, C1-8-alkyl substituted by halogen or cyano;
R3 is hydrogen, halogen, lower alkyl or lower alkyl substituted by halogen;
n is 1, 2 or 3; in case n is 2 or 3, R1 may be the same or different;
o is 1, 2 or 3; in case o is 2 or 3, R2 way be the same or different;
p is 1, 2 or 3; in case p is 2 or 3, R4 may be the same or different;
or a pharmaceutically active salt, a racemic mixture, an enantiomer, an optical isomer or a tautomeric form thereof.
2. A compound of formula I according to claim 1, wherein Ar1 is phenyl and Ar2 is phenyl.
3. A compound of formula I according to claim 2, wherein the compound is
4-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-benzonitrile 3-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-benzonitrile 4-({[(3RS,4SR)-1-(4-cyano-benzoyl)-4-(3,4-dichloro-phenyl)-pyrrolidin-3-yl]-methyl-amino}-methyl)-2-fluoro-benzonitrile 4-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-3-fluoro-benzonitrile {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl)-(2-fluoro-5-methanesulfonyl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-methanesulfonyl-phenyl)-methanone 4- {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-2-methyl-benzonitrile 1-(4-{(3SR,4RS)-3-(3,4-,dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-phenyl)-ethanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-y1}-(4-morpholin-4-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-y1}-(4-[1,2,4]triazol-1-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-imidazol-1-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-[4-(1,1-dioxo-1-6-isothiazolidin-2-yl)-phenyl]-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-pyridin-2-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-pyridin-3-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl)-(4-pyridin-4-yl-phenyl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-[1,3,4]oxadiazol-2-yl-phenyl)-methanone N-(4-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-phenyl)-acetamide 4-{(3SR,4RS)-3-(4-chloro-3-fluoro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-benzonitrile {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(4-oxazol-5-yl-phenyl)-methanone or 4-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[methyl-(4-trifluoromethyl-benzyl)-amino]-pyrrolidine-1-carbonyl}-benzonitrile.
4. A compound of formula I according to claim 1, wherein Ar1 is heteroaryl and Ar2 is phenyl.
4. A compound of formula I according to claim 1, wherein Ar1 is heteroaryl and Ar2 is phenyl.
5. A compound of formula I according to claim 4, wherein the compound is benzo[1,3]dioxol-5-yl-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3,fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(6-methyl-pyridin-3-yl)-methanone 5-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-pyridine-2-carbonitrile {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(6-morpholin-4-yl-pyridin-3-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-((3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(6-fluoro-pyridin-3-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-((3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(6-methoxy-pyridin-3-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(6-pyrazol-1-yl-pyridin-3-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(2-methyl-pyridin-4-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-y1}-(6-hydroxy-pyridin-3-yl)-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-[1,6]naphthyridin-2-yl-methanone {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-(2-methoxy-pyrimidin-5-yl)-methanone (3H-benzotriazol-5-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-methanone (3H-benzoimidazol-5-yl)-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-methanone 4-(5-{(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidine-1-carbonyl}-pyridin-2-yl)-piperazine-1-carboxylic acid tert-butyl ester or {(3SR,4RS)-3-(3,4-dichloro-phenyl)-4-[(3-fluoro-4-trifluoromethyl-benzyl)-methyl-amino]-pyrrolidin-1-yl}-[6-(1,1-dioxo-1-6-thiomorpholin-4-yl)-pyridin-3-yl]-methanone.
6. A process for preparing a compound of formula I as defined in claim 1, which process comprises a) coupling a compound of formula with an acid chloride or carboxylic acid of formula R-C(O)-Ar1-(R1)n wherein R is Cl or hydroxy, to a compound of formula wherein the substituents R1, R2, R3, Ar1, Ar2 and the definitions o, n and p are described in claim 1, or b) alkylating a compound of formula with a compound of formula Hal-CH2-Ar2-(R2)o to a compound of formula wherein the substituents R1, R2, R3, Ar1, Ar2 and the definitions o, n and p are described in claim 1, and, if desired, converting the compounds obtained into pharmaceutically acceptable acid addition salts.
7. A compound according to any on of claims 1-5, whenever prepared by a process as claimed in claim 6.
8. A medicament containing one or more compounds as claimed in any one of claims 1-5 and pharmaceutically acceptable excipients.
9. A medicament according to claim 8 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
10. The use of a compound as claimed in any one of claims 1-5 for the manufacture of medicaments for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08166184 | 2008-10-09 | ||
| EP08166184.5 | 2008-10-09 | ||
| PCT/EP2009/062585 WO2010040663A1 (en) | 2008-10-09 | 2009-09-29 | Pyrrolidine n-benzyl derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2738870A1 true CA2738870A1 (en) | 2010-04-15 |
Family
ID=41393630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2738870A Abandoned CA2738870A1 (en) | 2008-10-09 | 2009-09-29 | Pyrrolidine n-benzyl derivatives |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8293770B2 (en) |
| EP (1) | EP2331500A1 (en) |
| JP (1) | JP2012505173A (en) |
| KR (1) | KR20110063862A (en) |
| CN (1) | CN102177136A (en) |
| AU (1) | AU2009301212A1 (en) |
| BR (1) | BRPI0920306A2 (en) |
| CA (1) | CA2738870A1 (en) |
| IL (1) | IL211676A0 (en) |
| MX (1) | MX2011003312A (en) |
| WO (1) | WO2010040663A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110144081A1 (en) * | 2009-12-15 | 2011-06-16 | Henner Knust | Pyrrolidine derivatives |
| US8618303B2 (en) * | 2011-01-07 | 2013-12-31 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| MX347952B (en) * | 2011-05-13 | 2017-05-19 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors. |
| US9790210B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078322A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| AU2013344886B2 (en) | 2012-11-13 | 2017-06-29 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| BR112015010875B1 (en) | 2012-11-13 | 2022-05-03 | Array Biopharma Inc | N-PYRROLIDINYL, N-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS, THEIR PHARMACEUTICAL COMPOSITION, THEIR USE AND THEIR PROCESS FOR PREPARATION |
| US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US10835533B2 (en) | 2014-05-15 | 2020-11-17 | Array Biopharma Inc. | 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor |
| EP3183248B1 (en) | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
| WO2024020101A1 (en) * | 2022-07-21 | 2024-01-25 | The Regents Of The University Of California | Prostaglandin e synthase 3 (ptges3) inhibiting compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0311425A (en) * | 2002-05-31 | 2005-03-15 | Takeda Pharmaceutical | Compound, prodrug, method for preparing the compound, optically active alcohol, and ically active amine, and for preventing and / or treating abnormalities or diseases, medicament, and use of the compound or a prodrug thereof |
| AU2003902882A0 (en) * | 2003-06-10 | 2003-06-26 | Fujisawa Pharmaceutical Co., Ltd. | Piperidyl derivatives |
| BRPI0510951A (en) * | 2004-05-12 | 2007-11-20 | Pfizer Prod Inc | piperidine derivatives as nk1 and nk3 antagonists |
| KR20070094955A (en) | 2005-01-06 | 2007-09-27 | 에프. 호프만-라 로슈 아게 | Sulfanyl substituted phenyl methanones as glycine transporter 1(glyt-1) inhibitors for the treatment of neurological and neuropsychiatric disorders |
| ES2346335T3 (en) | 2005-01-07 | 2010-10-14 | F. Hoffmann-La Roche Ag | DERIVATIVES OF (4- (HETEROARIL) PIPERACIN-1-IL) - (PHENYLL 2,5-REPLACED) METANONE AS INHIBITORS OF THE GLICINE 1 CARRIER (GLYT-1) FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS. |
| WO2006115285A1 (en) * | 2005-04-21 | 2006-11-02 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
| WO2007015588A1 (en) * | 2005-08-04 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Piperidine derivative as tachykinin receptor antagonist |
| WO2007089031A1 (en) * | 2006-02-01 | 2007-08-09 | Takeda Pharmaceutical Company Limited | Piperidine derivatives as tachykinin receptor antagonists |
| BRPI0810402A2 (en) * | 2007-04-20 | 2014-11-04 | Hoffmann La Roche | PYROLIDINE DERIVATIVES AS TWO NK1 / NK3 RECEPTOR ANTAGONISTS |
| WO2009024502A1 (en) * | 2007-08-22 | 2009-02-26 | F. Hoffmann-La Roche Ag | Pyrrolidine aryl-ether as nk3 receptor antagonists |
| US8063075B2 (en) * | 2008-06-10 | 2011-11-22 | Hoffmann-La Roche Inc. | Pyrrolidine ether derivatives as NK3 receptor antagonists |
| WO2009153179A1 (en) * | 2008-06-16 | 2009-12-23 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives as nk2 receptor antagonists |
| US8022099B2 (en) * | 2008-11-03 | 2011-09-20 | Hoffmann-La Roche Inc. | N-benzyl pyrrolidine derivatives |
| MX2011007506A (en) * | 2009-01-30 | 2011-08-04 | Hoffmann La Roche | Piperidine derivatives as nk3 receptor antagonists. |
| US8318759B2 (en) * | 2009-02-18 | 2012-11-27 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives as NK3 receptor antagonists |
| US8394834B2 (en) * | 2009-08-25 | 2013-03-12 | Hoffman-La Roche Inc. | Pyrrolidines as NK3 receptor antagonists |
-
2009
- 2009-09-29 MX MX2011003312A patent/MX2011003312A/en unknown
- 2009-09-29 KR KR1020117010171A patent/KR20110063862A/en active IP Right Grant
- 2009-09-29 EP EP09783525A patent/EP2331500A1/en not_active Withdrawn
- 2009-09-29 JP JP2011530454A patent/JP2012505173A/en not_active Ceased
- 2009-09-29 AU AU2009301212A patent/AU2009301212A1/en not_active Abandoned
- 2009-09-29 CN CN2009801400102A patent/CN102177136A/en active Pending
- 2009-09-29 WO PCT/EP2009/062585 patent/WO2010040663A1/en active Application Filing
- 2009-09-29 CA CA2738870A patent/CA2738870A1/en not_active Abandoned
- 2009-09-29 BR BRPI0920306A patent/BRPI0920306A2/en not_active IP Right Cessation
- 2009-10-02 US US12/572,282 patent/US8293770B2/en not_active Expired - Fee Related
-
2011
- 2011-03-10 IL IL211676A patent/IL211676A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110063862A (en) | 2011-06-14 |
| JP2012505173A (en) | 2012-03-01 |
| US8293770B2 (en) | 2012-10-23 |
| IL211676A0 (en) | 2011-06-30 |
| EP2331500A1 (en) | 2011-06-15 |
| US20100168088A1 (en) | 2010-07-01 |
| AU2009301212A1 (en) | 2010-04-15 |
| MX2011003312A (en) | 2011-04-26 |
| BRPI0920306A2 (en) | 2019-09-24 |
| CN102177136A (en) | 2011-09-07 |
| WO2010040663A1 (en) | 2010-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8293770B2 (en) | Pyrrolidine derivatives as NK-3 receptor antagonists | |
| AU2008312635B2 (en) | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | |
| JP2017524026A (en) | Tideback benzamide derivatives as potent ROCK inhibitors | |
| CA2742463C (en) | 3-(benzylamin0)-pyrr0lidine derivatives and their use as nk-3 receptor antagonists | |
| CA2767770C (en) | Pyrrolidine derivatives as nk3 receptor antagonists | |
| JP2011522855A (en) | Pyrrolidine ether derivatives as NK3 receptor antagonists | |
| EP2661432B1 (en) | Pyrrolidine derivatives as nk3 antagonists | |
| EP2346848B1 (en) | Quinazoline derivatives as nk3 receptor antagonists | |
| EP2155729B1 (en) | Prolinamide-tetrazole derivatives as nk3 receptor antagonists | |
| US8859588B2 (en) | Substituted N-heteroaryl bipyrrolidine carboxamides, preparation and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140930 |